NZ568290A

NZ568290A - Method of detecting pathogens and in particular human papilloma virus (HPV)

Info

Publication number: NZ568290A
Application number: NZ568290A
Authority: NZ
Inventors: Csaba Jeney; Tibor Takacs
Original assignee: Genoid Kft
Priority date: 2005-11-15
Filing date: 2006-11-15
Publication date: 2011-12-22
Also published as: CN101360833A; BRPI0620507A2; DK1844164T3; PT1844164E; GB0523250D0; ES2348607T3

Abstract

Discloses a method of detecting the presence of at least one pathogen comprising contacting a nucleic acid obtained from a sample with a set comprising at least four probes wherein each of said probes comprises a sequence complementary to a sequence from a pathogen flanked by four pairs of complementary bases, wherein said bases form a stem structure in the absence of hybridization to a nucleic acid from pathogen, wherein said probe is labelled with a first interacting label and a second interacting label such that hybridizing of said probe to a nucleic acid from said pathogen causes a change in the signal detected. Further discloses a set of probes comprising at least four probes wherein each of said probes comprises a sequence complementary to a sequence from a pathogen flanked by four pairs of complementary bases, wherein said bases form a stein structure in the absence of hybridization to a nucleic acid from a pathogen, wherein said probe is labelled with a first interacting label and a second interacting label such that hybridizing of said probe to a nucleic acid from said pathogen causes a change in the signal detected.

Description

<div class="application article clearfix" id="description"> New Zealand Paient Spedficaiion for Paient Number 568290 Received at IPONZ on 13 July 2011 1 METHOD OF DETECTING PATHOGENS This invention relates to diagnostics specifically for organisms associated with 5 sexually transmitted diseases, and more particularly to detection of human papillomavirus (HPV) genotypes, particularly genital human papillomavirus genotypes. Human papillomavirus and its significance 10 According to the World Health Organization (WHO), cervical cancer is the second most common cause of cancer death in women. The presence of HPV infection has been implicated in more than 99% of cervical cancers worldwide. As estimated, more than 500,000 women worldwide develop cervical cancer in 15 every year, and more than 273,000 of the cases are fatal. Even with Pap screening programs, a significant number of women die from cervical cancer each year. HPV infection is the most frequent sexually transmitted disease (STD) 20 worldwide, and up to 60% of sexually active women will be infected by HPV in the genital tract once in their lifetime. Irrespective of HPV infection status, fewer than 1 in 10,000 women will develop invasive cervical cancer. The fact that most HPV-infected women do not develop cytological anomalies or cancer underlines the importance of factors modulating the progression of cervical 25 disease to cancer in HPV-infected women. These factors may include the HPV genotype and molecular variant, the HPV viral load, persistence of HPV infection, co-infection with other STD agents, the immune status of the host and environmental factors such as smoking. 524492v1 WO 2007/057669 PCT/GB2006/004266 Papillomaviruses are small DNA viruses that infect mammalian epithelial cells, causing epithelial proliferative lesions which may be benign, e.g., fibropapillomas (warts), or which may be malignant. All papillomaviruses are similar in that the genome size, organization, open reading frames, and protein 5 functions are shared. Many, but not all, genome regions are conserved among the various papillomaviruses. Because of the close association between the papillomavirus life cycle and the differentiation state of the host cell, the details of the papillomavirus life cycle 10 have not been completely elucidated. It is known that papillomaviruses infect host epithelial basal cells, where the viral genomes become established and are maintained as low copy-number episomes that replicate in coordination with host cell replication. As the infected cells differentiate into keratinocytes, viral DNA is amplified, the late genes are induced, and vegetative replication of the 15 papillomavirus follows. Papillomaviruses infect a wide variety of animals, including humans. The human papillomaviruses (HPV) (including Papillomaviridae family, Alpha-, Beta-, Gamma-, Delta-, Mupapillomavirus and unclassified Papillomaviridae 20 genera) are common causes of sexually transmitted disease. Several types of HPV have been identified by DNA sequence data, and 96 HPV genotypes have been fully sequenced to date. Genotyping of HPV is based on DNA sequences of the LI, E6, and E7 genes. A 10% difference in sequence with respect to previously established strains is sufficient to define a new type of virus. 25 The heterogeneity of the human papillomavirus group is generally described in deVilliers, 1989, J. Virology 63:4898-4903, which is incorporated herein by reference. The genomes of numerous HPV types have been sequenced and/or characterized. WO 2007/057669 PCT/GB2006/004266 3 HPVs are DNA tumour viruses whose genome is organized in three regions: the early gene (El to E7), the late gene (LI and L2) regions and the upper regulatory region (URR) or long control region (LCR). The URR possesses 5 binding sites for many repressors and activators of transcription, suggesting that it may play a part in determining the range of hosts for specific HPV types. El and E2, meanwhile, encode proteins that are vital for extrachromosomal DNA replication and the completion of the viral life cycle. The E2 encodes two proteins: one, which inhibits transcription of the early region; and the other, 10 which increases the transcription of the early region. A hallmark of HPV-associated cervical carcinoma is loss of the expression of the viral E2 proteins. Recently a new E2 protein, consisting of the product of the small E8 ORF with the part of the E2 protein, was described. This protein able to repress both viral replication and transcription, and is therefore believed to have a major role in 15 viral latency. The E4 protein is expressed in the later stages of infection when complete virions are being assembled, and is not known to have transforming properties; however it is considered to play an important role for the maturation and 20 replication of the virus. The E4 protein also induces the collapse of the cytoplasmic cytokeratin network in human keratinocytes, a situation which may assist the release of virions from the infected cell. The E5 open reading frame (ORF), meanwhile, is often deleted in cervical 25 carcinoma cells, indicating that it might not be essential in maintaining the malignant transformation of the host cell. When present, E5 interacts with various transmembrane proteins like the receptors of the epidermal growth factor, platelet-derived growth factor (3, and colony stimulating factor. A study WO 2007/057669 PCT/GB2006/004266 4 using HPV 16-infected cells found the E5 protein to possess weak transforming activity. In carcinogenesis, the E6 and E7 ORF are considered to play the most major 5 roles. These two units encode for oncoproteins that allow replication of the virus and the immortalization and transformation of the cell that hosts the HPV DNA. The late region units, LI and L2 encode viral capsid proteins during the late 10 stages of virion assembly. The protein encoded by LI is highly conserved among different papilloma virus species. The minor capsid protein encoded by L2 has more sequence variations than that of the LI protein. HPV can infect the basal epithelial cells of the skin or inner tissue linings, and 15 are, accordingly, categorized as either cutaneous or mucosal (anogenital) type. The HPV DNA is usually extrachromosomal or episomal in benign cervical precursor lesions. However, in many cervical cancer cells as well as in cervical cancer cell lines and HPV-transformed human keratinocytes in vitro, the HPV 20 DNA is integrated in the host genome. Cancer tissues may contain both episomal and integrated HPV DNAs at the same time, although integration appears to occur more frequently in HPV 18-associated cervical cancer than in HPV 16-associated cervical cancer. 25 Integrated HPV 16 is present in some premalignant lesions but is not always present in carcinomas. During HPV DNA integration, the viral genome usually breaks in the E1/E2 region. The break usually leads to the loss of the El and E2 regions. The loss of E2, which encodes proteins including one that inhibits the transcription of the E6 and E7 regions, has been known to result in WO 2007/057669 PCT/GB2006/004266 uncontrolled and increased expression of E6 and E7 oncogenic proteins. Increased expression of E6 and E7, meanwhile, has been observed to lead to the malignant transformation of the host cells and to tumour formation. HPV viral integration into the host genomic DNA is associated with progression 5 from polyclonal to monoclonal status in Cervical intraepithelial neoplasia (CIN), and these events play a fundamental role in the progression from low-grade to high-grade cervical neoplasia. Patterns of DNA copy number imbalance (CNI) are characteristic of cervical 10 squamous intraepithelial lesion (SIL) grade, human papillomavirus (HPV) status and postoperative recurrence. While some CNIs were seen at similar frequencies in HG-SIL (high grade SIL) and LG-SIL (low grade SIL), others, including gain on lq, 3q and 16q, were found frequently in HG-SIL but not in LG-SIL. There were significantly more CNIs per case in HG-SILs showing 15 loss of the HPVI6 E2 gene and in HG-SILs that subsequently recurred. The data are consistent with sequential acquisition of CNIs in cervical SIL progression. Higher frequency of CNI in association with E2 gene loss supports in vitro evidence that high-risk HPV integration is associated with genomic instability. 20 Based on the available molecular, clinical and epidemiologic data, a subset of HPVs are unequivocally the etiologic agents for cervical cancers and their precursors. HPVs have been detected in about 90% of cervical adenocarcinomas and squamous cell carcinomas. The majority of HPV 25 infections clear spontaneously, but persistent infection with HPV DNA has been found in metastases arising from cervical tumours. Nevertheless known high-risk (or oncogenic) HPV types are a significant risk factor for cervical cancer and are increasingly recognized for their role in other cancers. Virtually all cervical cancers (99%) contain the genes of high-risk HPVs, most WO 2007/057669 PCT/GB2006/004266 commonly types 16, 18, 31, and 45. Other high-risk types include types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, and 73. HPVs 31, 33, 35, 51 and 52 are sometimes regarded as "intermediate risks" because they are more common in mild or severe dysplastic lesions than in carcinomas. Among the high-risk 5 strains, HPV 16 and 18 are the most closely associated with cervical carcinoma. The HPVI6 DNA has been found in more than 50% of squamous cell carcinomas, while the HPVI8 DNA has been found in more than 50% of adenocarcinomas. However, the great majority of anogenital HPVs have oncogenic potential. 10 HPVs interaction with host cells has two principal biological consequences: a) All anogenital HPVs induce low grade squamous lesions, which are the morphologic correlate of a productive infection and the immortalisation phenotypes exerted by normal E6, E7 expression. The immortalisation is an 15 inherent strategy of papillomaviruses to mobilise resources for the DNA replication and produce new progeny. b) Rarely, HPVs induce a proliferative epithelial phenotype recognized as a high grade lesion and that is the proximate cytohistologic precursor of invasive cervical carcinoma, which might involve uncontrolled E6, E7 expression. 20 To date the clinical diseases, which are associated with HPV infections and the potential field of applications of HPV detection and typing methods include condyloma acuminatum, lichen sclerosus, squamosus cell hyperplasia, vulvar intraepithelial neoplasia, squamosus cell carcinoma, cervical intraepithelial 25 neoplasia, cervical carcinoma, adenocarcinoma of the cervix, anal intraepithelial neoplasia, penile intraepithelial neoplasia, adenocarcinoma of the larynx, recurrent respiratory papillomatosis, and epidermodysplasias verruciformis. Recent evidence suggests that HPV may play a role in the development of prostate cancer in men as well. WO 2007/057669 PCT/GB2006/004266 1 Cervical cancer precursor lesions (intraepithelial lesions) or cytological abnormalities are tested using Papanicolaou Stain, known as the Pap Smear after the inventor George Papanicolaou. The technique involves smearing 5 cervical scrapes on a glass slide, and staining the cells obtained from the anogenital tract with hematoxylin, a nuclear stain. The Pap smear, however, has a lack of repeatability and it is not sufficiently predictive of impending HPV-induced neoplasias. It has been shown that 25% of patients with advanced in situ carcinoma may present normal Pap smears a few years before diagnosis or 10 the last negative cytology was uniformly positive in cervical cancer cases on re-examination. An increasingly prevalent problem is the occurrence of invasive cancer within 3 years of a negative Pap smear. The current acceptable rate of false negatives (i.e., women who do have 15 dysplasia according to an expert panel of pathologists looking at tissue biopsies rather than smear samples, but are not diagnosed that way during the routine smear screening) is roughly 5-10% but recent studies suggest that the actual rate may be much higher. Furthermore, in approximately 7-8% of cases, the Pap smear demonstrates atypical squamous cells of undetermined significance 20 (ASCUS). In an additional 20-30% of cases, the Pap smear may be insufficient for interpretation due to the presence of inflammatory cells. In the case of the cervix, flat warts (visualised by colposcopy) are suspected premalignant lesions. Histopathological progression of flat warts to carcinoma in situ and cervical cancer has been well described. 25 Intraepithelial lesions are common early events among women with incident HPV infection, and the interval between incident HPV-16 or HPV-18 infection and biopsy-confirmed CIN grade 2-3 appears to be relatively short. However studies have demonstrated that infection with high-risk HPV types is usually WO 2007/057669 PCT/GB2006/004266 8 transient. Persistence of HPV infection substantially increases the risk of progression to high grade intraepithelial lesions and invasive disease. The progression of the disease is variable and it is associated with the loss or 5 persistence of HPV. Significant numbers of dysplastic lesions regress spontaneously, others fail to progress, while a few progress rapidly. As a consequence of the preferential role of high-risk genotypes in cervical cancer and because of the different, consequential and characteristic type 10 patterns for the other pathological conditions, both identification and typing of HPV is highly important. Additionally different types of high-risk HPV pose different risks to the affected individuals. For instance, HPV16 and HPVI8 have been more consistently identified in higher grades of cervical dysplasia and carcinoma than other HPV types. HPVI6 is also more prevalent in 15 squamosus carcinoma cases, and HPV18 is more prevalent in adenocarcinoma cases. HPV diagnostics 20 From 1980, several viral genomes have been cloned and used as type-specific probes in the diagnosis of HPVs. Filter hybridization techniques have been used to detect HPV DNA in cervical scrapes collected in parallel with samples for routine cytology. HPV DNA probes have been used in different hybridization-based assays such as Southern and hybrid Dot/Southern assays to 25 detect HPV DNA in clinically-derived tissue samples. Additionally, purified biopsy DNA and in situ hybridizations in preserved tissue specimens, that is, direct localization within the intact cell of those sequences complementary to the nucleic acid probes have been demonstrated. WO 2007/057669 PCT/GB2006/004266 A method for detecting HPV DNA types that utilizes a reverse-blotting procedure has been reported. The procedure involved forming a membrane to which genomic DNA from four different HPV types was bound and then hybridizing labelled DNA from a biological sample to the DNA bound to the 5 membrane. Numerous methods have been developed to detect human papillomavirus types . using type-specific reaction, detecting one HPV type at a time. The Polymerase Chain reaction (PGR) has been used to amplify and detect the presence of 10 HPVI6 and HPV 18 DNA , in particular to detect HPVI6 in oral and cervical biopsies. A mixture of primers has been described for the specific amplification by PGR of HPV sequences in types la, 5, 6a, 8, 11, 16, 18, and 33. U.S. Pat. Nos. 4,683,195 and 4,683,202 disclose PGR and the use of PGR to detect the presence or absence of nucleic acid sequence in a sample. 15 U.S. Pat. No. 5,447,839, which is incorporated herein by reference, discloses a method for detection and typing of HPV. In this method, HPV DNA sequences in a sample are amplified by PGR using consensus primers which amplify both oncogenic and non-oncogenic HPV types. Thus, the presence of HPV in the 20 sample is indicated by the formation of amplification products. HPV is then typed using type-specific DNA probes which hybridize with the amplified region of DNA. The type-specific hybridization probes disclosed in this patent are capable of identifying and distinguishing among five known oncogenic types of HPV, namely HPV-6, HPV-11, HPV-16, HPV-18 and HPV-33. 25 A variety of methods for detecting high-risk types of HPV have been devised. Many of these rely on the detection of unique sequences in the HPV genome. For example, DNA or RNA probes complementary to a portion of the genes of a particular high risk HPV strain have been reported in the art, as useful in WO 2007/057669 PCT/GB2006/004266 screening for the presence of a particular strain of high-risk HPV in patient samples (U.S. Pat. No. 4,849,332, incorporated herein by reference). U.S. Pat. No. 5,705,627., incorporated herein by reference, reports use of PGR to amplify and detect HPV DNA using degenerate or mixed consensus primers, 5 followed by typing using a mixture of genotype-specific DNA probes. Other examples of using consensus primers can be found in U.S. Pat. No. 5,364,758, and Kleter, B. et al., Am. J. of Pathology, vol. 153, No. 6, 1731-39 (1998). These references are also incorporated herein by reference. 10 There is a commercial method available, which is based on hybridisation and signal amplification. (Hybrid Capture II, Digene Corp.) However, this method reportedly has specificity problems due to the high sequence homology of some part of the HPV genomes. 15 The amplification based methods consist of a part responsible for sensitivity (amplification), which is separated from those parts responsible for specificity (detection by hybridisation). These techniques differ in the amplified genome section, the number of primers and the techniques of detection. The most often used amplification methods are GP5+-GP6+ (general primer - GP), MY9-20 MY11, PGMY, SPF, L1C and the type specific PGR reactions. The most often used detection techniques are sequence specific hybridization, restriction fragment length polymorphism (RFLP) and line probe assay (LiPA). Sometimes, but rarely, sequencing or other methods are applied. The analytical properties of the amplifications vary within a wide range and are characterised 25 by the number genotypes, which can be amplified, the analytical sensitivity, specificity of the amplification/detection of genotypes and also by the differences of sensitivities between genotypes. WO 2007/057669 PCT/GB2006/004266 11 HPV real-time PGR Human papillomavirus-16 (HPV-16) viral load could be a biomarker predictive of the presence of high-grade cervical lesions. Several real-time PGR assays 5 have been developed to accurately measure HPV-16 viral load (HPV-16 LI, HPV-16 E6, and HPV-16 E6 PG). The methods are teaching us to perform HPV detection in real-time, but detecting only one genotype at a time. Identification of HPV DNA in patients with juvenile-onset recurrent respiratory 10 papillomatosis was carried out using SYBR® Green real-time PGR. The method is used to detect multiple human papillomavirus genotypes in a realtime PGR reaction. , However the amplification method is different from that described in the present invention. The amplicon produced is longer (approx. 450 bp), than is accepted for a probe based real-time amplification method in 15 the art.The prefered length is 150 bp or less. The detection method is aspecific and unable to differentiate the genotypes reliably, which necessitates subsequent viral typing using real-time PCR with type-specific primers for HPV types 6, 11, 16, 18, 31, and 33. This again detects the types of human papillomavirus in isolates, but only one genotype at a time. 20 Similarly others used a method where a single-tube nested reaction was used to detect human papillomavirus genotypes in a general manner. However, specific detection of groups were not described. 25 Another method was used to detect human papillomavirus DNA in sex partners again using a two-step approach to assess both the genotypes and viral load data. The method uses GP5+/6+ polymerase chain reaction (PCR), followed by reverse-line blot analysis. It was used for the detection of 45 HPV types in cervical and penile scrape samples. Viral loads were subsequently determined 30 in scrape samples positive for HPV types 16, 18, 31, and 33 by a LightGycler- WO 2007/057669 PCT/GB2006/004266 based real-time PCR assays. The GP5+/GP6+ PCR generates an amplicon of 150 bp length, enabling the application of the real-time probe based methods However the method can not detect multiple genotypes or groups in one reaction. 5 A method for homogeneous real-time detection and quantification of nucleic acid amplification was devised using restriction enzyme digestion. In this homogeneous system detection is mediated by a primer containing a reporter and quencher moiety at its 5' terminus separated by a short section of DNA 10 encoding a restriction enzyme recognition sequence. In the single stranded form, the signal from the fluorescent reporter is quenched due to fluorescence resonance energy transfer (FRET). However, as the primer becomes incorporated into a double stranded amplicon, a restriction enzyme present in the reaction cleaves the DNA linking the reporter and quencher, allowing 15 unrestricted fluorescence of the reporter. This system was tested using a primer specific for the E6 gene of human papilloma virus (HPV) 16 combined with the cleavable energy transfer label and used to amplify HPV16 positive DNA. The method can not be used for the detection of multiple genotypes or groups. 20 A real-time PCR-based system for simultaneous quantification of human papillomavirus types associated with high risk of cervical cancer has also been described. A real-time PCR assay for the detection and quantification of HPV16, -18, -31, -33, -35, -39, -45, -52, -58, and -67 was developed. The assay is based on three parallel real-time PCRs from each patient sample: (i) reaction 25 1 detects and quantifies HPV16, -31, -18, and -45 (HPV18 and -45 were detected and quantified together using one probe) with three different fluorophores; (ii) reaction 2 detects and quantifies HPV33, -35, -39, -52, -58, and -67 (HPV33, -52, -58, and -67 were detected and quantified together), again with three different fluorophores and only three different probes were WO 2007/057669 PCT/GB2006/004266 13 used; and (iii) reaction 3 detects and quantifies the amount of a human single copy gene (HMBS, Homo sapiens hydroxymethylbilane synthase; GenBank accession no. M95623.1). Reaction 1 includes a total of seven PCR primers and three probes, reaction 2 includes a total of seven PCR primers and three probes, 5 and reaction 3 includes two PCR primers and a single probe. The method applies TaqMan hydrolysable real-time PCR probes. The use of only three probes in one reaction detecting a maximum of 6 genotypes in the same reaction is described. The method cannot be used as a general teaching to design reactions detecting multiple HPV genotypes, because the sequence 10 identities between genotypes are limited. Extension of the reaction is restricted by using sequence identities between genotypes. A method for the detection and quantitation of oncogenic human papillomavirus (HPV) was previously developed by using the fluorescent 5' exonuclease assay. The method is based on the amplification of a 180-bp 15 fragment from the 3' part of the El open reading frame in a single PCR with type-specific probes for HPV types 16, 18, 31, 33, and 35. The probes can be used separately or in combinations of up to three probes per assay. The method was limited to three probes per assay. 20 A strategy for human papillomavirus detection and genotyping with SybrGreen and molecular beacon polymerase chain reaction has also been described. The assay, accomplishes general HPV detection by SybrGreen reporting of HPV-DNA amplicons, and genotyping of seven prevalent HPV types (HPV-6, -11, -16, -18, -31, -33, -45) by real-time molecular beacon PCR. The two step 25 method uses three differently labelled molecular beacons in one PCR reaction. Another method has also been described: a degenerate HPV self-probing fluorescent primer known as Scorpion and a mixture of Scorpions was used in conjunction with a tailed general primer. By utilizing a tailed primer, it was WO 2007/057669 PCT/GB2006/004266 14 possible to introduce a consensus site that enables a single Scorpion to recognize many different HPV amplicons. This is a two-step procedure that can theoretically detect over 40 different HPV types. 10 Scorpion typing primers were used in this study (HPV6, 11, 16, 18, 31, 33, 39, 45, 51, 56). The primer 5 sequence of each Scorpion is type specific and is located at the same sequence position as that of the GP6+ primer of Jacobs et al. The method teaches a general detection method to detect the presence of HPV and a type specific detection method used to type the positive samples. It does not solve the problem of screening with multiplexed probes, which leads to probe cross-10 reactivity. In fact the method avoids using of multiple probes in one reaction. Real-time PCR based HPV detection' methods using the real-time LightCycler™ and TaqMan™ assays have been compared to conventional GP5+/6+ PCR/enzyme immunoassay (EIA) to assess the human 15 papillomavirus load in cervical scrape specimens. Both real-time PCR assays determined the HPVI6 load in scrape specimens similarly, but there was low agreement between these assays and the GP5+/6+ PCR/EIA, suggesting that the latter method is not suited for quantifying HPV DNA. Also HPV6/11 and HPV 16/18 DNA loads have been determined by real-time fluorogenic 20 quantitative PCR detecting the two HPV gene types at a time . Consensus primer design methods Primers and probes that are used to detect only one human papillomavirus 25 nucleic acid molecule, e.g., a nucleic acid molecule encoding a portion of the LI, can be designed using, for example, a computer program such as OLIGO (Molecular Biology Insights Inc., Cascade, Colo.) or Primer3. Appropriate features of these oligonucleotides are well known for those skilled in the art. WO 2007/057669 PCT/GB2006/004266 15 There is extensive literature on the general principles of PCR primer design, which have led to a number of software applications, most notably Primer3 and various extensions. A fast dynamic programming formulation for testing primers for pair-wise compatibility has also been developed. The application of 5 multiplex PCR has increased steadily over the past decade, requiring more sophisticated primer selection protocols. Different algorithms may favor particular objectives, or may be designed for particular technology platforms. In general, the problem of identifying primer pairs to maximize the multiplexing level of a single assay has been shown to be NP-complete. An 10 approximation algorithm that eliminates 3' base complementarity while addressing product size constraints has been presented. The method of the invention is related to the problem of designing multiplex PCR assays, particularly the design of consensus primers. The general 15 approach of this problem is to design consensus primers to amplify numerous target with less primer pairs than the number of targets. Moreover the design would take into account the design rules of multiplex PCR assays as well, exemplified by a consensus herpesvirus. 20 A particular approach to identify distantly related gene sequences based on consensus-degenerate hybrid oligonucleotide primers (CODEHOPs) was developed. Short regions of proteins with high levels of conservation can be represented as ungapped blocks of multiply aligned protein sequences. CODEHOPs are derived from these conserved sequence blocks and are used in 25 PCR to amplify the region between them. A CODEHOP PCR primer consists of a pool of primers each containing a different sequence in the 3' degenerate core region where each primer provides one of the possible codon combinations encoding a targeted 3-4 conserved amino acid motif within the sequence block. In addition, each primer in the pool has an identical 5' WO 2007/057669 PCT/GB2006/004266 16 consensus clamp region derived from the most probable nucleotide at each position encoding the conserved amino acids flanking the targeted motif. Amplification initiates by annealing and extension of primers in the pool with the most similarity in the 3' degenerate core to the target template. Annealing is 5 stabilized by the 5' consensus clamp which partially matches the target template. Once the primer is incorporated, it becomes the template for subsequent amplification cycles. Because all primers are identical in the 5' consensus clamp region, they all will anneal at high stringency during subsequent rounds of amplification. This method has been used in the field of 10 virology as well. The approach is different from the method of the invention, where specific sequence blocks are used to achieve efficient amplification of related sequences. The Codehop program finds primers for amplifying unknown targets but works with protein sequence alignments instead of DNA sequences. 15 There are numerous methods dealing with the design of consensus/degenerate primers, but they generally use different algorhythms to solve basically the same problem: to identify the best-fit primer set for efficient amplification of the related target sequences. Cooperation between primers is not taken into 20 account: Another approach is the PriFi program Chttp://cgi-www. d aimi. au. dk/c gi-chili/PriFi/maiii). This designs pairs of primers useful for PCR amplification of genomic DNA in species where prior sequence information is not available. 25 The program works with an alignment of DNA sequences from phylogenetically related species and outputs a list of possibly degenerate primer pairs fulfilling a number of criteria, such that the primers have a high probability of amplifying orthologous sequences in other phylogenetically WO 2007/057669 PCT/GB2006/004266 17 related species. However the program does not use the concept of cooperation between primers. The Amplicon program for designing PCR primers on aligned groups of DNA 5 sequences is a similar method. The most important application for Amplicon is the design of'group-specific' PCR primer sets that amplify a DNA region from a given taxonomic group but do not amplify orthologous regions from other taxonomic groups. Again, the cooperation between primers was not taken into account. 10 The design of amplification reaction primers for detection by targeting numerous, related amplification targets has no straightforward rules in the literature. However it is generally accepted that the unforeseeable interactions between primers and the competition for amplification resources lower the 15 sensitivity of the reaction and more primers means a larger probability of mispriming producing aspecific products competing further for the resources. The potential role of HPV testing in cervical carcinoma screening is highly dependent on the existing infrastructure. For clinical settings in which an 20 effective, well-organized, cytology based program is in place, the issue is whether HPV testing adds to the existing program and questions of cost effectiveness, quality control, and added value to current practice come to the fore. In contrast, for settings in which screening is nonexistent, or is ineffective because of poor-quality cytology or inherent limitations due to a high rate of 25 inflammatory smears, the more basic questions of sensitivity, specificity, and simplicity of testing procedures become paramount. The real-time PCR technology offers features which fulfil and even exceed the requirements in both scenarios described above. A recent study determined the WO 2007/057669 PCT/GB2006/004266 18 amount of HPV DNA for some of the most frequent high-risk HPV types as determinants of progression to cervical malignancies (CIS). The range of copy numbers per cell does not differ between HPV types but the odds ratio for CIS in the percentile with highest viral load is substantially higher for HPV 16 (OR 5 = 36.9; 95% CI = 8.9-153.2) than for HPV 31 (OR = 3.2; 95% CI = 1.1-9.1) or HPV 18/45 (OR = 2.6; 95% CI = 1.0-6.4). Therefore, HPV viral load may be predictive of future risk of cervical CIS at a stage when smears are negative for squamous abnormalities. The real-time technologies offer the premises to determine the viral load more exactly than the existing HPV detection methods. 10 Real-time technology offers several advantages over the existing methods. However no real-time amplification and detection methods have been developed which can detect more than three human papillomavirus types in one reaction. Also, no method has been developed to detect clinically important groups of the virus, e.g. low-risk or high-risk human papillomaviruses in 15 groups in one reaction. An accurate self-sampled HPV test could have enormous implications. Such a test opens up the possibility of evaluating women who are otherwise unwilling or unable to submit to pelvic examinations. In underdeveloped areas this would 20 offer an advantage over the current practice. In areas where organized screening is in place, self-sampling offers an additional approach for reaching women who refuse to have conventional screening and also may have a role in surveillance or the monitoring after the treatment of HPV-positive cytology-negative women, in which follow-up testing at short intervals is needed. The 25 self-sampling approach with near-patient testing capabilities could improve the quality and accessibility of the screening programs. A HPV test, which targets both the conventional and the primary screening market, should satisfy all of these needs. Real-time PCR technology is Received at IPONZ on 13 July 2011 19 (followed by page 19a) especially suitable to address these requirements technologically. The inherent simplicity of the technology helps to reduce infrastructure barriers and it is also cost-effective over other technologies. On the other side the real-time PCR technologies could boost the analytical sensitivity and more importantly the specificity of HPV detection, providing a more solid basis of the improvement of the clinical counterparts of these parameters. Internal control adds quality control capabilities to the system. In the near-patient application of HPV detection the real-time technologies are the most feasible options. The near-patient testing would be the next frontier in primary screening and the real-time technologies are already attracted significant attention in this field in case of other pathogens and could provide added values in practice. The increased sensitivity of real-time PCR compared to other methods, as well as the feature improvements provided by real-time PCR including sample containment and real-time detection of the amplified product indicate the feasibility of implementation of this technology for routine diagnosis of human papillomavirus infections in the clinical laboratory. In the first aspect, the present invention provides a method of detecting the presence of at least one pathogen comprising contacting a nucleic acid obtained from a sample with a set comprising at least four probes wherein each of said probes comprises a sequence complementary to a sequence from pathogen flanked by four of complementary bases, wherein said bases form a stem structure in the absence of hybridization to a nucleic acid from a pathogen, wherein said probe is labeled with a first interacting label and a second interacting label such that hybridizing of said probe to a nucleic acid from a pathogen causes a change in the signal detected. Received at IPONZ on 13 July 2011 19a (followed by page 20) The invention also provides a set of probes comprising at least four probes wherein each of said probes comprises a sequence complementary to a sequence from a pathogen flanked by four pairs of complementary bases, 5 wherein said bases form a stem structure in the absence of hybridization to a nucleic acid from a pathogen, wherein said probe is labeled with a first interacting label and a second interacting label such that hybridizing of said probe to a nucleic acid from said pathogen causes a change in the signal detected. 10 The invention also provides a kit for detecting one or more pathogens comprising a set of probes of the invention. The invention also provides a kit for detecting one or more HPV genotypes 15 comprising a set of probes of the invention. 524492v1 WO 2007/057669 PCT/GB2006/004266 20 As used herein, "nucleic acid" refers to DNA and RNA in its various forms such as mRNA, and hnRNA. The nucleic acid can be single stranded or double stranded. 5 As used herein a "pathogen" means a biological agent that disrupts the normal physiology of an animal, that causes or is associated with disease and illness. The pathogen may be a causative agent, i.e. infection of a patient with the pathogen produces the disease either alone, or in the presence of one more other 10 cofactors. Preferably the pathogen is an organism associated with a sexually transmitted disease. As used herein the term "organism associated with a sexually transmitted disease" refers to an organism that is present in patients suffering 15 from the sexually transmitted disease. Examples of organisms associated with a sexually transmitted disease include Chlamydia trachomatis which is associated with chlamydia, Neisseria gonorrhoeae which is associated with Gonorrhoea, Herpes simplex virus (HSV) which is associated with genital herpes, Human pappillomavirus which is associated with genital warts and 20 Treponema pallidum which is associated with Syphilis. The organism is preferably a virus, more preferably a human pappillomavirus (HPV). The method is preferably used to detect the presence of one or more HPV genotypes. 25 Although the method of the present invention relates to the detection of a pathogen, this method can be used to detect the presence or absence of any organism, particularly organisms which contain more than one sub-species, or related organisms. As used herein, "related organisms" refer to organisms which are from the same class, genus or species, and have a high level of WO 2007/057669 PCT/GB2006/004266 21 genetic similarity, preferably at least 80 % identity, more preferably 90%. The related organisms are preferably viruses, more preferably human papillomaviruses. 5 Each of the probes preferably has the general structure 3' - stem -F- HPV complementary sequence - F'- stem' - 5' F and F' are optional linking sequences which connect the complementary 10 sequences to the flanking base pairs, stem and stem'. Stem and stem' are the sequences formed by the complementary base pairs which form a double-helix stem structure in the solution. These sequences are preferably palindromic. There are preferably 4 bases at each end of the probe. The bases making up the stem preferably comprise C-G pairs, preferably 1, 2, 3, 4 or 5 C-G pairs. The 15 stem preferably has the sequence CGCG. It was determined in our experiments that the four base pair -stem molecular beacons do not interact with each other causing unforeseeable false amplification signal over time in the absence of detectable target DNA, which 20 seems to depend on the on-off rate of the stem structure. Occasionally five-base pair stem molecular beacons need to be used to optimise the reaction. Beacons with longer stems both in singleplex and multiplex detection exerted uncontrollable false amplification signals. Shorter stemmed beacons usually have too low melting temperatures to be useful in real-time amplification 25 reaction. The term "interacting label" as used herein refers to one of a pair of labels which cooperates with the other of the pair of the labels. This cooperation occurs when the labels are in close proximity, such as when the probes have a WO 2007/057669 PCT/GB2006/004266 22 stem loop structure. When the probe hybridizes to a complementary nucleic acid, the cooperation between the labels is diminished, or removed completely as the distance between them is increased. The labels are attached to the probes at each end of the probe, preferably either on or adjacent to the complementary 5 bases that form the stem loop structure. If is not important where the labels are attached provided that a change in signal can be detected when the probe changes from one conformation to the other i.e. stem loop to open. The change in signal can be an increase in signal when the probe is in the open position i.e. when it is hybridized to a complementary nucleic acid sequence, for example 10 when one interacting label quenches the signal from the second interacting label. Alternatively the change in signal can be a decrease in signal when the probe is in the open position when it is hybridized to a complementary nucleic acid sequence, for example where the first interacting label causes a signal to be emitted from the second interacting signal. 15 In a preferred embodiment the interacting labels are a FRET donor and a corresponding FRET acceptor. FRET technology (see, for example, U.S. Pat. Nos. 4,996,143, 5,565,322, 20 5,849,489, and 6,162,603) is based on the fact that when a donor and a corresponding acceptor fluorescent moiety are positioned within a certain distance of each other, energy transfer takes place between the two fluorescent moieties that can be visualized or otherwise detected and/or quantitated. As used herein, the FRET technology format utilizes molecular beacon technology 25 to detect the presence or absence of a human papillomavirus. Molecular beacon technology uses a hybridization probe labelled with a donor fluorescent moiety and an acceptor fluorescent moiety. The fluorescent labels are typically located at each end of the probe. Molecular beacon technology uses a probe oligonucleotide having sequences that permit secondary structure formation WO 2007/057669 PCT/GB2006/004266 23 (e.g., a hairpin). As a result of secondary structure formation within the probe, both fluorescent moieties are in spatial proximity when the probe is in solution. After hybridization to the target nucleic acids (i.e. the HPV genotype nucleic acid), the secondary structure of the probe is disrupted and the fluorescent 5 moieties become separated from one another such that after excitation with light of a suitable wavelength, the emission of the first fluorescent moiety is different to that detected in the absence of a nucleic acid from a HPV genotype. As used herein with respect to donor and corresponding acceptor fluorescent 10 moieties, "corresponding" refers to an acceptor fluorescent moiety having an emission spectrum that overlaps the excitation spectrum of the donor fluorescent moiety. The wavelength maximum of the emission spectrum of the acceptor fluorescent moiety preferably should be at least 100 nm greater than the wavelength maximum of the excitation spectrum of the donor fluorescent 15 moiety. Accordingly, efficient non-radiative energy transfer can be produced there between. Fluorescent donor and acceptor moieties are generally chosen for (a) high efficiency Forster energy transfer; (b) a large final Stokes shift (>100 nm); (c) 20 shift of the emission as far as possible into the red portion of the visible spectrum (>600 nm); and (d) shift of the emission to a higher wavelength than the Raman water fluorescent emission produced by excitation at the donor excitation wavelength. For example, a donor fluorescent moiety can be chosen that has its excitation maximum near a laser line (for example, Helium-25 Cadmium 442 nm or Argon 488 nm), a high extinction coefficient, a high quantum yield, and a good overlap of its fluorescent emission with the excitation spectrum of the corresponding acceptor fluorescent moiety. A corresponding acceptor fluorescent moiety can be chosen that has a high extinction coefficient, a high quantum yield, a good overlap of its excitation WO 2007/057669 PCT/GB2006/004266 24 with the emission of the donor fluorescent moiety, and emission in the red part of the visible spectrum (>600 nm). Representative donor fluorescent moieties that can be used with various 5 acceptor fluorescent moieties in FRET technology include fluorescein, Lucifer Yellow, B-phycoerythrin, 9-acridineisothiocyanate, Lucifer Yellow VS, 4-acetamido-4!-isothio-cyanatostilbene-2,2'-disulfonic acid, 7-diethylamino-3-(4'-isothiocyanatophenyl)-4-methylcoumarin, succinimdyl 1-pyrenebutyrate, 4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid derivatives, optionally 10 substituted pyrenes, anthracenes, naphthalenes, acridines, stilbenes, indoles, benzindoles, oxazoles, benzoxazoles, thiazoles, benzothiazoles, 4-amino-7-nitrobenz-2-oxa-l,3-diazoles, cyanines, carbocyanines, carbostyryls, porphyrins, salicylates, anthranilates, azulenes, perylenes, pyridines, quinolines, coumarins, polyazaindacenes, xanthenes, oxazines, benzoxazines, 15 carbazines, phenalenones, benzphenalenones, carbazines, oxazines, 4-bora-3a,4a-diaza-s-indacenes, fluorophoresceins, rhodamines, rhodols, 5-carboxyfluorophoresceins (FAM), 5-(2'-aminoethyl) aminonapthalene-1-sulfonic acids (EDANS), anthranilamides, terbium chelates, Reactive Red 4, Texas reds, ATTO dyes, EVO Dyes, DYO Dyes, Alexa dyes and BODIPY 20 dyes. Representative acceptor fluorescent moieties, depending upon the donor fluorescent moiety used, include LC.TM.-RED 640 (LightCycler.TM.-Red 640-N-hydroxysuccinimide ester), LC.TM.-RED 705 (LightCycler.TM.-Red 25 705-Phosphoramidite), cyanine dyes such as CY5 and CY5.5, Lissamine rhodamine B sulfonyl chloride, tetramethyl rhodamine isothiocyanate, rhodamine x isothiocyanate, erythrosine isothiocyanate, fluorescein, diethylenetriamine pentaacetate or other chelates of Lanthanide ions (e.g., Europium, or Terbium). Donor and acceptor fluorescent moieties can be WO 2007/057669 PCT/GB2006/004266 25 obtained, for example, from Molecular Probes (Junction City, Oreg.) or Sigma Chemical Co. (St. Louis, Mo.). Preferably, the acceptor fluorescent moiety is a quencher. As used herein, a 5 quencher is a moiety which decreases the fluorescence emitted by the fluorescent label. This includes complete and partial inhibition of the emission of the fluorescence. The degree of inhibition is not important as long as a change in fluorescence can be detected once the quencher is removed. 10 The quenching moiety is preferably selected from the group consisting of optionally substituted phenyls, naphthyls, anthracenyls, benzothiazoles, benzoxazoles, or benzimidazoles, pyrenes, anthracenes, naphthalenes, acridines, stilbenes, indoles, benzindoles, oxazoles, benzoxazoles, thiazoles, benzothiazoles, 4-amino-7-nitrobenz-2-oxa-l,3-diazoles, cyanines, 15 carbocyanines, carbostyryls, porphyrins, salicylates, anthranilates, azulenes, perylenes, pyridines, quinolines, coumarins, polyazaindacenes, xanthenes, oxazines, benzoxazines, carbazines, phenalenones, benzphenalenones, carbazines, oxazines, 4-bora-3a,4a-diaza-s-indacenes, fluorophoresceins, rhodamines, rhodols, 5-carboxyfluorophoresceins (FAM), 5-(2'-aminoethyl) 20 aminonapthalene-1-sulfonic acids (EDANS), anthranilamides, terbium chelates, Reactive Red 4, dabcyls, nitrotyrosines, malachite greens, Texas reds, dinitrobenzenes, ATTO dyes, EVO Dyes, DYO Dyes, Alexa dyes and BODIPY dyes. 25 The selection of suitable pairs of FRET donors and acceptors or quenchers is within the knowledge of the skilled person. Generally, when the FRET is detected in an amount, which is statistically different from the amount of FRET in a sample lacking the human WO 2007/057669 PCT/GB2006/004266 26 papillomavirus nucleic acid molecule the presence of a human papillomavirus infection in the individual is indicated. Hybridisation of the probe to the nucleic acid increases the distance between the donor and acceptor moiety, and thus the FRET interaction is reduced. The change in wavelength emission detected can 5 be an increase in emission or emission at a different wavelength, such as when a quencher is used. Alternatively there can be a decrease in emission or emission at a different wavelength when a non-quenching donor acceptor is used. 10 Fluorescent analysis can be carried out using, for example, a photon counting epifluorescent microscope system (containing the appropriate dichroic mirror and filters for monitoring fluorescent emission at the particular range), a photon counting photomultiplier system, or a fluorometer. Excitation to initiate energy transfer can be carried out with an argon ion laser, a high intensity mercury 15 (Hg) arc lamp, a fiber optic light source, or other high intensity light source appropriately filtered for excitation in the desired range. The donor and acceptor fluorescent moieties are preferably attached to the probe on the linking sequences. The donor and acceptor fluorescent moieties 20 can be attached to the appropriate probe oligonucleotide via a linker arm. The length of each linker arm also is important, as the linker arms will affect the distance between the donor fluorescent moiety and the acceptor fluorescent moiety. The length of a linker arm for the purpose of the present invention is the distance in Angstroms (ANG) from the nucleotide base to the fluorescent 25 moiety. In general, a linker arm is from about 10 to about 25 ANG. The linker arm may be of the kind described in WO 84/03285. WO 84/03285 also discloses methods for attaching linker arms to particular nucleotide bases, and also for attaching fluorescent moieties to a linker arm. WO 2007/057669 PCT/GB2006/004266 27 The probe must have a sufficient level of identity with the nucleic acid of the pathogen or organism associated with a sexually transmitted disease so that it can hybridize with nucleic acid from one or more pathogens or organisms associated with a sexually transmitted disease under suitable conditions. One 5 single-stranded nucleic acid is said to hybridize to another if a duplex forms between them. This occurs when one nucleic acid contains a sequence that is the reverse or complement of the other (this same arrangement gives rise to the natural interaction between the sense and antisense strands of DNA in the genome and underlies the configuration of the double helix). Complete 10 complementarity between the hybridizing regions is not required in order for a duplex to form; it is only necessary that the number of paired bases is sufficient to maintain the duplex under the hybridization conditions used. It is often desirable to have one or more mismatches between the sequence of the probe and that of the genome of the pathogen. This is necessary to prevent the 15 formation of unwanted secondary structures within the probe. Thus in one preferred embodiment the sequence unique to the pathogen within the probe contains at least one mismatch with the genomic sequence of the pathogen. . Suitable hybridization conditions are well known to the person skilled in the art. For example 0.2xSSC/0.1% SDS at 42° C. (for conditions of moderate 20 stringency); and O.lxSSC at 68° C. (for conditions of high stringency). Washing can be carried out using only one of the conditions given, or each of the conditions can be used (for example, washing for 10-15 minutes each in the order listed above). Any or all of the washes can be repeated. Optimal conditions will vary and can be determined empirically by the skilled person. 25 The degree of identity between the probe and the pathogen's nucleic acid will vary depending on the function of the probe. For example the probe can be used to identify the presence of all sub-species of the pathogen, for example all HPV genotypes, in which case the probe will have a sequence which will WO 2007/057669 PCT/GB2006/004266 28 hybridize to a sequence from a region of the nucleic acid which is highly conserved between all sub-species, such as HPV genotypes. A probe can be used to detect the presence of pathogens, e.g. HPV genotypes, 5 from a certain risk group, e.g. high risk or low risk genotypes or others. The sequence of the probe will be designed accordingly. For example a probe can be designed to detect high risk genotypes which can bind to types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, and 73, but not nucleic acids from other genotypes. These are referred to as "risk group probes". 10 Alternatively each probe can have a sequence which has a high level of similarity to a variable region of a one specific genotype, so that it hybridises only to a nucleic acid from that genotype. Such probes are called "genotype specific". The members of the human papillomavirus type-specific probes can 15 hybridize within defined genotype-specific regions, preferably those comprising SEQ ID. NOS: 53 to 103 on the amplified DNA. The HPV genotype specific probes preferably comprise a sequence selected from SEQ ID. NOS: 33 to 52 or SEQ ID. Nos. 105 to 117. These sequences form all or part of the sequence unique to the pathogen. 20 The set of probes comprises at least four probes, preferably 5,10,15 or 20 different probes. The probes are carefully designed so that the sequence contained with the "loop" of the stem loop structure, not only hybridise with the desired sequence in the nucleic acid to be detected, but so they do not form 25 secondary structures with sequences in the loops of other probes. Thus the sequences for the loop part of the probes are generally not just a sequence which is 100% complementary to the sequence in the genome to be detected. Preferably, the human papillomavirus type-specific probes can hybridize within defined type-specific regions, preferably those comprising SEQ ID. NOS: 53 to Received at IPONZ on 13 July 2011 29 103 or SEQ ID. Nos. 105 to 117. In one preferred embodiment each probes comprises a sequence selected from SEQ ID. NOS: 33 to 52 or SEQ ID. Nos. 105 to 117. In a particularly preferred embodiment the set of probes comprises: 5 5'TET-CGGCGGGTCATCCTTATTTTTCCATAAGCCG-Dabcyl-3' 5'TET-CGGCGGGACATCCATATTACTCTATCAAAGCCG-Dabcyl-3' 5'TET-CGCGGGTCACCCTTATTACTCTATTACAAAACGCG-Dabcyl-3' 5'TET-CCGGCACCCATATTTCCCCCTTAAACCGG-Dabcyl-3' 5'TET-CCGGACGACCAGCAAACAAGACACCCGG-Dabcyl-3' 10 5'FAM-CGGCCAATAACAAAATATTAGTTCCTAAAGCCG-Dabcyl-3' 5'FAM-CCGGTATCCTGCTTATTGCCACCCCGG-Dabcyl-3' 5'FAM-CGGCCATACCTAAATCTGACAATCCGCCG-Dabcyl-3' 5'FAM-GCCGTTTTTTAGCGTTAGTAGGATTTTTCGGC-Dabcyl-3' 5 'FAM-CGGCAAAACAAGATTCTAATAAAATAGCAGCCG-Dabcyl-3' 15 5'FAM-CGGCTTAAAGTGGGTATGAATGGTTGGCCG-Dabcyl-3' 5 'FAM-CCGGGCTGTTCCTAAGGTATCCGCCGG-Dabcyl-3' 5'FAM-CGGCAGCACGCGTTGAGGTTTTAGCCG-Dabcyl-3' 5'FAM-CCGGAGTTTTAGTTCCCAAGGTGTCCCGG-Dabcyl-3' 5'FAM-CCCGCTGTGACTAAGGACAAT ACCAAACGGG-Dabcyl-3' 20 5'FAM-CGGCTTCCATCAAAAGTCCCAATAACGCCG-Dabcyl-3' 5 'FAM-CGGC AAAGGTGGT AATGGTAGAC AGGGCCG-Dabcyl-3' 5'FAM-CGGCAATCTGGTACCAAAACAAACATCGCCG-Dabcyl-3' 5'FAM-CGGCTTAAGGTTCCTATGTCTGGGGGCCG-Dabcyl-3' and 5' (Texas Red)-TTTTTT-(fluorescein)-25 CGGCTGAC ATAGATCCCC ATAGAC AGTTGCCG-Dabcyl-3' The presence of pathogens from a particular risk group can be detected in two ways. Firstly "risk-group" probes can be used. Preferably the set of probes contains more than one type of risk group probe, wherein each type is 30 differentially labelled. For example a high risk group probe can be distinguished from a low risk probe. Therefore the presence of a pathogen, such as HPV, from either risk group can be detected. Alternatively the set of probes can comprise genotype specific probes, wherein all the probes for genotypes from a certain risk group, e.g. high risk genotypes are all labelled with the same 35 interacting labels. Thus the identity of the specific genotypes present can not be 524492v1 WO 2007/057669 PCT/GB2006/004266 30 determined, but the presence of a genotype from a certain group can be confirmed. In a preferred embodiment the method further comprises determining the 5 melting temperature of the double stranded nucleic acid molecule formed by one of said probes and complementary nucleic acid obtained from said sample. As each of the probes has a certain nucleic acid sequence, the melting temperature of the double stranded nucleic acid molecule formed by the probes and the complementary nucleic acid obtained from said sample is unique for 10 each probe. Thus the specific pathogen or genotype present can be detected. For example a set of genotype specific probes for a certain risk group can be used to ascertain if any genotypes from that group are present. The melting temperature can then be determined to identify which specific genotypes are present. 15 The method of detecting HPV types individually can be performed after the method has been performed to detect human papillomavirus family, genera or groups or concurrent with the method to detect human papillomavirus. 20 If more than one probe is used, they can preferably be distinguished from one another, i.e. each probe emits a detectably different signal when excited at a certain wavelength. Thus is two probes are used, one will emit at a wavelength when it is hybridised to nucleic acid from the pathogen that can be distinguished from both the probes in solution (i.e. not hybridised to the 25 nucleic acid from the pathogen such as the HPV genotype) and the other probe when it is hybridised to the nucleic acid from the pathogen. This allows the presence of both probes hybridised to the nucleic acid to be visualised at the same time. Alternatively the two probes are labelled with different interacting labels, for example FRET donors, which are excited at different wavelengths. WO 2007/057669 PCT/GB2006/004266 31 This can be achieved by using different combinations of interacting labels, such FRET donors and acceptors. The selection of suitable combinations of interacting labels is routine to the person skilled in the art. 5 The method preferably detects the presence of four or more pathogens or genotypes, utilising four or more probes. Preferably the probes are bound to a solid phase such that each type of probe is at a spatially defined location which is distinguishable from the other probe locations. This allows probes labelled with the same or similar interacting labels which produce a signal at the same 10 or similar wavelengths to be used, whilst still providing a means for distinguishing the signal produced by each probe. Alternatively the probes can be labelled so that different signals are produced by each type of probe. The skilled person will understand that a range of possible solid supports are in common usage in the area of arrays and any of these "substrates" can be 15 utilized in the production of arrays of probes of the present invention. In one preferred embodiment there is provided a method for constructing a reaction for the detection targeting of numerous, related detection targets using at least four real-time molecular beacon probes in one reaction. The method 20 includes the selection of probe binding sites, determining the sequence of probes which satisfy the usually applied criteria on probes (e.g. checking the probes against a computer program at full complementarity like Primer3) and adding bases, preferably four or five bases, to the sequence of probe, at both ends, rendering them to be complementary and capable to form double-25 stranded stems involving exactly the two very ends of the same oligonucleotides. These structures are generally called four-stem molecular beacons. Additionally the melting point of the probe sequence should be higher than the melting point of the stem structure, when measured at near equilibrium heating and cooling rates. The four base-stem molecular beacons are generally WO 2007/057669 PCT/GB2006/004266 32 advantageous over other stem length having shorter on-off rates than the longer stems, and having higher melting temperature than the shorter stem molecular beacons. 5 Generally, the members of the probe mixtures hybridize to the amplification product within a certain defined type-specific region. The probes are typically labelled with a donor fluorescent moiety at one end and at other end they are typically labelled with a corresponding acceptor or quencher fluorescent moiely. In some embodiments the donor fluorescent moiety may contain a 10 specific complex of fluorescent dyes, including so called harvester dyes, to shift the wavelength of the emission of the probe to provide an unique fluorescent signal for detection. The method further includes detecting the presence, absence or change in fluorescent resonance energy transfer (FRET) between the donor fluorescent moiety and the acceptor or quencher fluorescent 15 moiety. The presence of or change in FRET is indicative of the presence of human papillomavirus in the biological sample, while the absence of FRET is indicative of the absence of human papillomavirus in the biological sample. Generally, the nucleic acid is hybridized with the probe and excited at a 20 wavelength absorbed by the donor fluorescent moiety. The presence or absence of the bound probe is detected by visualizing and/or measuring the wavelength emitted by the acceptor or quencher fluorescent moiety. Alternatively it can be detected by quantitating the FRET. 25 In one preferred embodiment the nucleic acid obtained from a sample is amplified prior to being contacted with said set of probes. Preferably the amplification is carried out using the polymerase chain reaction (PCR). The amplification reaction may be PCR (see for example U.S. Patents Nos. 4,683,195 and 4,683,202, and Innis et al, editors, PCR Protocols, (Academic WO 2007/057669 PCT/GB2006/004266 Press, New York, 1989; Sambrook et al, Molecular Cloning, Second Edition, (Cold Spring Harbour Laboratory, New York 1989)). PCR will can also be used when RNA has been isolated and converted, preferably by reverse transcription, to cDNA. Preferably, PCR is carried out using Taq DNA 5 polymerase, e.g. Amplitaq™ (Perkin-Elmer, Norwalk, Conn.). Taq polymerase can also be obtained from MBI Fermentas, Perkin Elmer, Boehringer Mannheim and Beckman Instruments. An equivalent, preferably thermostable, DNA polymerase may also be used in the method of the present invention, such as Tfl {Thermits flavus) polymerase (Gut et al, Virol. Methods 77(1): 37-46 10 (1999)). Alternatively, the amplification reaction may be RT-PCR (Yajima et al, Clin. Chem, 44(12): 2441-2445 (1998); Martell et al, J. Clin. Microbiol., 37(2): 327-332 (1999); Gut et al, Virol. Methods 77(1): 37-46 (1999); Predhomme et al, 15 Leukemia, 13(6): 957-964 (1999)), in which RNA is reverse transcribed into cDNA which is then subjected to PCR amplification. As is well-known, PCR involves the extraction and denaturation (preferably by heat) of a sample of DNA (or RNA). A molar excess of oligonucleotide 20 primers is added, along with a polymerase, which may be heat-stable, and dNTPs for forming the amplified sequence. The oligonucleotide primers are designed to hybridise to opposite ends of the sequence desired for amplification. In the first round of amplification, the polymerase replicates the DNA to produce two "long products," which begin with the respective primers. 25 The total DNA, which includes the two long products and the two original strands, is then denatured and a second round of polymerisation is carried out (for example, by lowering the temperature). The result of the second round is the two original strands, the two long products from the first round, two new long products (produced from the original strands), and two "short products" WO 2007/057669 PCT/GB2006/004266 34 produced from the long products. These short products have the sequence of the target sequence (sense or antisense) with a primer at each end. For each additional amplification round, the number of short products grows exponentially, each round producing two additional long products and a 5 number of short products equal to the sum of the long and short products remaining at the end of the previous round. Oligonucleotide primers can be synthesised by a number of approaches, e.g. Ozaki et al, Nuc. Acids Res. 20: 5205-5214 (1992); Agrawal et al, Nuc. Acids 10 Res. 18: 5419-5423 (1990) or the like. Conveniently, the oligonucleotide probes are synthesised on an automated DNA synthesiser, e.g. an Applied Biosystems, Inc, Foster City, California model 392 or 394 DNA/RNA synthesiser using standard chemistries such as phosphoramidite chemistry (Beaucage and Iyer, Tetrahedron 48: 2223-2311 (1992), US Patent Nos. 15 4980460, 4725677, 4415732, 4458066 and 4973679). Alternative chemistries, including non-natural backbone groups such as phosphorothioate and phosphoramidate, may also be employed, provided that the hybridisation efficiencies of the resulting oligonucleotides are not adversely affected. The precise length and sequence of the DNA primers will depend on the target 20 polynucleotide to be amplified. Preferably, the length of the DNA primers is in the range 10 to 60 nucleotides and more preferably in the range 15 to 30 or 25 nucleotides. Preferably, the production of the amplified nucleic acid is monitored 25 continuously. As used herein "monitored continuously" means that the amount of amplified product is measured on a regular basis. For example a reading can be taken after the first amplification cycle, and thereafter after every one, two, or five cycles. Alternatively measurements of the amount of amplified product present can be taken after a certain time period, e.g. every one, two, five or ten WO 2007/057669 PCT/GB2006/004266 seconds. This allows the process to be monitored in "real-time". The person skilled in the art would understand that the level of signal produced by the bound probes will fluctuate as the cycles passes through the various stages of annealing, amplification, and denaturing. 5 Conventional PCR methods in conjunction with FRET technology can be used to practice the methods of the invention. In one embodiment, a rapid thermocycler such as LIGHTCYCLER™ instrument is used. A detailed description of the LIGHTCYCLER™ System and real-time and on-line 10 monitoring of PCR can be found on Roche's website. The following patent applications describe real-time PCR as used in the LIGHTCYCLER.™. technology: WO 97/46707, WO 97/46714 and WO 97/46712. The LIGHTCYCLER™ instrument is a rapid thermocycler combined with a micro volume fluorimeter utilizing high quality optics. This rapid 15 thermocycling technique uses thin glass cuvettes as reaction vessels. Heating and cooling of the reaction chamber are controlled by alternating heated and ambient air. Due to the low mass of air and the high ratio of surface area to volume of the cuvettes, very rapid temperature exchange rates can be achieved within the thermal chamber. The instrument allows the PCR to be monitored in 20 real-time and on-line. Furthermore, the cuvettes serve as an optical element for signal collection (similar to glass fiber optics), concentrating the signal at the tip of the cuvette. The effect is efficient illumination and fluorescent monitoring of micro volume samples. The carousel that houses the cuvettes can be removed from the instrument. Therefore, samples can be loaded outside of 25 the instrument (in a PCR Clean Room, for example). In addition, this feature allows for the sample carousel to be easily cleaned and sterilized. The fluorimeter, as part of the apparatus, houses the light source. The emitted light is filtered and focused by an epi-illumination lens onto the top of the cuvette. Fluorescent light emitted from the sample is then focused by the same lens, WO 2007/057669 PCT/GB2006/004266 36 passed through a dichroic mirror, filtered appropriately, and focused onto data-collecting photohybrids. The optical unit in the instrument preferably includes three band-pass filters (530 nm, 640 nm, and 710 nm), providing six-colour detection and several fluorescence acquisition options. The present invention, 5 however, is not limited by the configuration of a commercially available instrument. Data collection options include once per cycling step monitoring, fully continuous single-sample acquisition for melting curve analysis, continuous sampling (in which sampling frequency is dependent on sample number) and/or stepwise measurement of all samples after defined temperature 10 interval. The thermocycler is preferably operated using a PC workstation and can utilize a Windows NT operating system. Signals from the samples are obtained as the machine positions the capillaries sequentially over the optical unit. The software can display the fluorescence signals in real-time immediately after each measurement. Fluorescent acquisition time is 10-100 15 msec. After each cycling step, a quantitative display of fluorescence vs. cycle number can be continually updated for all samples. The data generated can be stored for further analysis. In a preferred embodiment the nucleic acid is amplified utilising at least one 20 primer selected from Seq Id Nos 1 to 32, more preferably using a primer mixture comprising Seq Id Nos 1 to 32. In one preferred embodiment the method utilises an artificial or natural internal control DNA, preferably by detecting signal or FRET emission at a different, 25 distinguishable wavelength or regardless of the emission wavelengths used detecting, the emission changes at a spatially distinguishable location of solid phases bound probes. WO 2007/057669 PCT/GB2006/004266 37 The above-described methods can further include preventing amplification of contaminant nucleic acids from previous amplification reactions. Preventing such unwanted amplification can include performing the amplifying step in the presence of uracil and treating the biological sample with uracil-DNA 5 glycosylase prior to a first amplification step. In addition, the cycling step can be performed on a separate control sample, to confirm proper amplification conditions. A control sample can include a portion of the human papillomavirus nucleic acid molecule. Alternatively, such a control sample can be amplified using a pair of control primers and hybridized using a pair of 10 control probes. A control amplification product is produced if control template is present in the sample, and the control probes hybridize to the control amplification product. The methods of the present invention are carried out on nucleic acids obtained from a biological sample. Representative biological samples include cervical scraping, biopsies, smear or paraffin tissue sections, other scrapings of anatomical sites where human papillomavirus infection takes place and urine. Preferably the sample is selected from bronchial aspirates, urine, prostata massate, ejaculatum, blood and cervical, vulvar, anal, genital, skin or laryngeal cytological samples, scrapings or biopsies. In a second aspect the present invention provides a set of probes comprising least four probes wherein each of said probes comprises a sequence complementary to a sequence from a pathogen flanked by four pairs of 25 complementary bases, wherein said bases form a stem structure in the absence of hybridization to a nucleic acid from a pathogen, wherein said probe is labeled with a first interacting label and a second interacting label such that hybridizing of said probe to a nucleic acid from said pathogen causes a change in the signal detected. 15 20 WO 2007/057669 PCT/GB2006/004266 38 The preferred embodiments of the first aspect relating to the probes apply to the second aspect. 5 As described above, the sequences that form the "loop" part of the probe are selected so that they not only hybridize with the desired sequence in the target organism, but also so they do not form secondary structures with the loop regions of other probes. Thus in the third aspect the present invention provides a nucleic acid sequence comprising any one of SEQ ID Nos. 33 to 52 or SEQ 10 ID Nos. 105-117. These nucleic acid sequences can be used in other methods to detect the presence of one or more HPV genotypes. Thus the present invention also provides the use of a nucleic acid of the invention for detecting the presence or absence of at least one HPV genotype. Preferably the nucleic acid is used in a method which continuously monitors the amplification of nucleic 15 acid obtained from a sample. Such methods include TAQMAN™ technology, the use of the sequences as part of a molecular scorpion, and other PCR based methods. 20 TAQMAN™ technology detects the presence or absence of an amplification product, and hence, the presence or absence of human papillomavirus. TAQMAN™ technology utilizes one single-stranded hybridization probe labelled with two fluorescent moieties. When a first fluorescent moiety is excited with light of a suitable wavelength, the absorbed energy is transferred 25 to a second fluorescent moiety according to the principles of FRET. The second fluorescent moiety is generally a quencher molecule. During the annealing step of the PCR reaction, the labelled hybridization probe binds to the target DNA and is degraded by the 5' to 3' exonuclease activity of the Taq Polymerase during the subsequent elongation phase. As a result, the excited Received at IPONZ on 13 July 2011 39 fluorescent moiety and the second fluorescent moiety become spatially separated from one another. As a consequence, upon excitation of the first fluorescent moiety in the absence of the second fluorescent, the fluorescence emission from the first fluorescent moiety is detectably altered. For example if 5 the second fluorescent moiety is a quencher, the fluorescence emission from the first fluorescent moiety increases and thus can be detected. By way of example, an ABI PRISM™ 7700 Sequence Detection System (Applied Biosystems, Foster City, Calif.) uses TAQMAN™ technology, and is suitable for performing the methods for detecting human papillomavirus. Information 10 on PCR amplification and detection using an ABI PRISM™ 7700 system can be found on Applied Biosystems' website. In a further aspect described is a method of identifying a minimal set of primers which amplify nucleic acid sequences from two or more related organisms 15 comprising: (a) Identifying primer binding sites which have at least 30% identity between said organisms; (b) Designing a set of primers capable of initiating amplification at the primer sites identified in (a), wherein each of said primers has no more than 3 20 mismatches to a primer binding site in at least one of said organisms and wherein each of said primers differs from each of said primers by 4 or less nucleotides; (c) Determining the smallest number of primers required to detect the largest possible number of said organisms; 25 (d) Determining the relative amount of each primer required in said primer set to ensure equal amplification of the nucleic acid sequences from all of said organisms. 524492v1 WO 2007/057669 PCT/GB2006/004266 40 As used herein, "related organisms" refer to organisms which are from the same class, genus or species, and have a high level of genetic similarity, preferably at least 80 % identity, more preferably at least 90% identity. The related organisms are preferably viruses, more preferably human 5 papillomaviruses. The primers preferably amplify the LI region of human papillomaviruses. The percent identity of two nucleic acid sequences is determined by aligning the sequences for optimal comparison purposes (e.g., gaps can be introduced in 10 the first sequence for best alignment with the sequence) and comparing the nucleotides at corresponding positions. The "best alignment" is an alignment of two sequences which results in the highest percent identity. The percent identity is determined by the number of identical nucleotides in the sequences being compared (i.e., % identity = number of identical positions/total number 15 of positions x 100). The determination of percent identity between two sequences can be accomplished using a mathematical algorithm known to those of skill in the art. An example of a mathematical algorithm for comparing two sequences is the 20 algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264-2268, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877. The NBLAST and XBLAST programs of Altschul, et al. (1990) J. Mol. Biol. 215:403-410 have incorporated such an algorithm. BLAST nucleotide searches can be performed with the NBLAST program, 25 score = 100, wordlength = 12 to obtain nucleotide sequences homologous to nucleic acid molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (1997) Nucleic Acids Res. 25:3389-3402. Alternatively, PSI-Blast can be used to perform an iterated search which detects distant relationships between WO 2007/057669 PCT/GB2006/004266 molecules (Id.). When utilizing BLAST, Gapped BLAST, and PSI-Blast programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. Another example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, 5 CABIOS (1989). The ALIGN program (version 2.0) which is part of the CGC sequence alignment software package has incorporated such an algorithm. Other algorithms for sequence analysis known in the art include ADVANCE and ADAM as described in Torellis and Robotti (1994) Comput. Appl. Biosci., 10 :3-5; and FASTA described in Pearson and Lipman (1988) Proc. Natl. 10 Acad. Sci. §5:2444-8. Within FASTA, ktup is a control option that sets the sensitivity and speed of the search. A minimal set of primers is a set of primers containing the smallest number of primers required to amplify nucleic acid sequences from as many related 15 organisms as necessary. The set of primers can optionally contain a correction primer which is used to control priming differences between the primers at a particular primer binding site. The correction primers should have no more than three mismatches to the primer binding site where they are designed to act. The addition of correction primers helps to produce a level of sensitivity in 20 detection which is at least two orders of magnitude or greater for all of the organisms intended to be detected e.g. all human papillomaviruses. As used herein "mismatch" refers to when a base in a primer does not form a base-pair according to the Watson-Crick base pairing rules with a 25 corresponding base in the primer binding site. A mismatch is formed where the two corresponding bases do not conform to the Watson- Crick criteria e.g. C-T, G-A. The mismatches are preferably within the half of the primer nearest the 5' end, more preferably forming the 3 nucleotides before the 5' end of primer. WO 2007/057669 PCT/GB2006/004266 42 Each of the primers in the primer set only differs from the each of the other primers in the set by four or less nucleotides. Thus if the primers are all 15 nucleotides in length then 11 nucleotides in one primer are identical to 11 nucleotides in each of the other primers. The identical nucleotides are 5 preferably not continuous. In one preferred embodiment there is provided a method for constructing a highly complex multiplex reaction for human papillomavirus amplification. The method includes the selection of conserved primer binding sites (less than 10 70% variability) at an appropriate proximity. The primer binding sites should be located at a distance from each other to ensure that an amplicon of the appropriate size is produced. Preferably an amplicon of 30-160 nucleotides in length is produced, more preferably 40-120, 50-100, 60-90 or 70-80 nucleotides in length. Amplicons between 130 and 160 nucleotides in length 15 are particularly preferred. The primers form part of the amplicon generated. The primers are preferably 10-30 nucleotides in length, more preferably 12-25, 15-22 or 18, 19, 20 or 21 nucleotides in length. The sequence of a complete set of primers where primers are satisfying the usually applied criteria for primers (e.g. checking the primers against a computer program at full 20 complementarity like Primer3) is then determined, and the smallest possible number of primers are designed having only three mismatches, preferably on one end of the primer, more preferably the 5' end, to all of the related organisms, such as human papillomavirus types, which are intended to be amplified. Additionally the primers should bind to a nearly equal number of 25 types with no more than three mismatches. Further amplification differences are controlled by changing the relative concentration of the primers. The resulting sensitivity of detection is preferably within at least two magnitudes for all related organisms, such as the human papillomavirus types, which are intended to be detected. Received at IPONZ on 13 July 2011 43 (followed by page 43a) This is a significant achievement over the techniques in recent art, where sequential addition of the primers, and trial and error methods are followed. The devised method keeps the competition at a minimum. There are corrected priming efficiencies against all targets, resulting in highly equal amplification 5 sensitivities. Additionally the probability of mispriming is reduced by keeping the primers preferably variable at the 5' end thereof. The mixture of primers is capable of amplifying at least one human papillomavirus type LI region, preferably comprising Seq ID Nos. 53 to 103. It 10 preferably includes at least one forward primer from the group Seq Id Nos. 1 to 16 and at least one reverse primer from the group Seq ID Nos 17 to 32. In a further aspect the present aspect provides a set of primers obtainable by the primer identification method described above comprising at least one primer 15 selected from Seq.ID. Nos 1 to 32. Preferably it comprises at least one forward primer from the group Seq Id Nos. 1 to 16 and at least one reverse primer from the group Seq ID Nos 17 to 32. More preferably it comprises Seq.ID. Nos 1 to 32. 20 In a further aspect the present invention provides a kit for detecting one or more one or more pathogens comprising a set of probes as defined in the second aspect. The kit preferably further comprises a set of primers identified according to the primer identification method described above. 25 In addition, described is a kit for detecting one or more pathogens comprising a set of primers identified according to the primer identification described above. 524492v1 Received at IPONZ on 13 July 2011 43a (followed by page 44) The invention also provides a kit for detecting one or more HPV genotypes comprising a set of probes as described in the invention. 524492v1 WO 2007/057669 PCT/GB2006/004266 44 Preferably the kits can be used to detect one ore more organisms associated with a sexually transmitted disease, preferably HPV genotypes. Preferably the probes comprise a sequence selected from Seq ID nos. 17 to 33. The set of primers preferably comprise at least one sequence selected from Seq Id Nos 1 5 to 32, more preferably at least one selected from Seq ID No 1 to 16 and at least one selected from Seq Id 17-32. Most preferably the primer mixture comprises the primers of Seq Id Nos. 1-32. Preferably the kits further comprise an internal control. 10 The kit can also include a package label or package insert having instructions thereon for using the mixture(s) of primers and pair(s) of probes to detect the presence or absence of human papillomavirus in a biological sample. 15 The kits can further comprise other components, such as reagents required for PCR. Such reagents include buffers, a suitable DNA polymerase, and dNTPs such as dATP, dCTP, dGTP and dTTP. The kit components can be presented in a number of vials or other containers. The reagents may be lyophilised for later reconstitution prior to use. Alternatively the components can be provided in 20 suitable buffered solutions ready for use. Such solutions may contain suitable preservatives. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art 25 to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, and other Received at IPONZ on 13 July 2011 45 (followed by page 45a) references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. 5 In this specification where reference has been made to patent specifications, other external documents, or other sources of information, this is generally for the purpose of providing a context for discussing the features of the invention. Unless specifically stated otherwise, reference to such external documents is not to be construed as an admission that such documents, or such sources of information, in any jurisdiction, 10 are prior art, or form part of the common general knowledge in the art. In the description in this specification reference may be made to subject matter that is not within the scope of the claims of the current application. That subject matter should be readily identifiable by a person skilled in the art and may assist in putting into practice the invention as defined in the claims of this application. 15 The term "comprising" as used in this specification means "consisting at least in part of'. When interpreting each statement in this specification that includes the term "comprising", features other than that or those prefaced by the term may also be present. Related terms such as "comprise" and "comprises" are to be interpreted in the same manner. 20 The invention is illustrated by the following non-limiting examples. Other features, objects, and advantages of the invention will be apparent from the drawings and detailed description, and from the claims. 524492V1 Received at IPONZ on 13 July 2011 45a (followed by page 46) Example 1 Real-time PCR detection of high risk and low risk HPV DNA 5 The total reaction-volume was 20 pi, including the following components: 2pl (~0,2pg) cloned HPV DNA, 18pl polymerase buffer (final concentration: 90 mM TRIS-HC1 (pH=8,0), ImM DTT, 50 mM KC1, 7 mM MgCl2, 1% Tween-20 (SIGMA), 1% Ficoll, 1% PVP, 250 pM each dNTP (ATP, CTP, GTP, TTP)(Promega), 0,28 pM of each primers: SEQ. ID. NO: 1-10 32, 0,18 pM each of molecular beacons SEQ. ID. NO:33-52, and 7,5 U AmpliTaq Gold DNA polymerase (ROCHE) ). The reaction was carried out in LightCycler 2.0 PCR thermal cycler, with the following parameters: Step 1:10 minutes at 95 °C; Step 2: 5 minutes at 55 °C; 15 Step 3: Cycles 1-37: 30 seconds at 95 °C, 60 seconds at 42 °C - single detection mode, and 30 seconds at 72 °C; The high risk HPV genotypes were detected by molecular beacons SEQ. ID. NO:38-51. The fluorescent data were collected at 530nm. The low risk HPV genotypes were detected by molecular beacons SEQ. ID. 20 NO:33-37. The fluorescent data were collected at 560nm. The reaction internal control was detected by molecular beacon SEQ. ID. NO:52. The fluorescent data was collected at 610nm. 524492v1 WO 2007/057669 PCT/GB2006/004266 46 The following genotypes were succesfully detected: low-risk (6, 11, 42 ,43, 44/55), high-risk (16, 18, 31, 33 ,35 ,39, 45, 51 ,52, 56, 58, 59, 66, 68) and internal control. 5 Example 2 Real-time PCR detection of HPVl 6. HPVl 8 and HPV6. HPVl 1 HPV DNA The total reaction-volume was 20 jal, including the following components: 2fil (~0,2pg) cloned HPV DNA, 18|_l1 polymerase buffer (final 10 concentration: 90 mM TRIS-HC1 (pH=8,0), lOmM DTT, 50 mM KC1, 7 mM MgCl2, 1% Tween-20 (SIGMA), 1% Ficoll, 1% PVP, 250 fxM each dNTP (ATP, CTP, GTP, TTP) (Promega), 0,28 yM of each primers: SEQ. ID. NO: 1-32, 0,18 pM each of molecular beacons SEQ. ID. NO:33, 34, 38, 39, 52, and 7,5 U AmpliTaq Gold DNA polymerase (ROCHE) ). The reaction was carried 15 out in LightCycler 2.0 PCR thermal cycler, with the following parameters: Step 1: 10 minutes at 95 °C; Step 2: 5 minutes at 55 °C; Step 3: Cycles 1-37: 30 seconds at 95 °C, 60 seconds at 42 °C - single detection mode, and 30 seconds at 72 °C; 20 The HPV 16 and HPV 18 genotypes were detected by molecular beacons SEQ. ID. NO:38-39. The fluorescent data were collected at 530nm. The HPV6 and HPV11 genotypes were detected by molecular beacons SEQ. ID. NO:33-34. The fluorescent data were collected at 560nm. The reaction internal control was detected by molecular beacon SEQ. ID. 25 NO:52. The fluorescent data was collected at 610nm. The following genotypes were succesfully detected: low-risk (6, 11), high-risk (16,18) and internal control. WO 2007/057669 PCT/GB2006/004266 47 Appendix 1 Forward primers: SEQ. ID. NO: 1 KP-F/1 CGC ACC AAC ATATTTT ATT 5 SEQ. ID. NO:2 KP-F/2 CGCACAAGCATCTATTATTA SEQ. ID. NO:3 KP-F/3 CGCACAAGCATATTTTATC SEQ. ID. NO:4 KP-F/4 CGCACCAGTATATTTTATCA SEQ. ID. NO:5 KP-F/5 CGCACAAGCATTTACTATCA SEQ. ID. NO:6 KP-F/6 CGCACCAACTACTTTTACC 10 SEQ. ID. NO:7 KP-F/7 CGTACCAGTATTTTCTACCAC SEQ. ID. NO:8 KP-F/8 CGCACAGGCATATATTACT SEQ. ID. NO:9 KP-F/9 CGCACCAACATATATTATCA SEQ. ID. NO: 10 KP-F/10 CGTACCAACCTGTACTATTATG SEQ. ID. NO: 11 KP-F/11 GCACCAACTTATTTTACCAT 15 SEQ. ID. NO:12 KP-F/12 ACCAACCTCTTTTATTATGG SEQ. ID. NO: 13 KP-F/13 AGCACAAATATATATTATTATGG SEQ. ID. NO:14 KP-F/14 CGCACCGGATATATTACT SEQ. ID. NO: 15 KP-F/15 CGCACAAATATTTATTATTATGC SEQ. ID. NO: 16 KP-F/16 CGGACGAATGTTTATTACC 20 Reverse primers: SEQ. ID. NO:17 L1C2 TACCCTAAATACTCTGTATTG SEQ. ID. NO: 18 L1R2 TACCCTAAATACCCTATATTG 25 SEQ. ID. NO:19 R1 AATTCTAAAAACTCTGTACTG SEQ. ID. N0:20 R45 TACTCTAAATACTCTGTATTG SEQ. ID. NO:21 R11 TACCTTAAACACTCTATATTG SEQ. ID. NO:22 R16 TATTCTAAATACCCTGTATTG SEQ. ID. NO:23 R42 AACTCTAAATACTCTGTACTG 30 SEQ. ID. NO:24 R44 CATCTTAAAAACCCTATATTG SEQ. ID. NO:25 R03 AACCCTAAACACCCTGTATTG SEQ. ID. NO:26 R04 AACGCGAAAAACCCTATATTG SEQ. ID. NO:27 R05 TACCCTAAAGACCCTATACTG SEQ. ID. NO:28 R06 AACTCTAAATACCCTATACTG 35 SEQ. ID. NO:29 R07 AACGTGAAATACACGATATTG SEQ. ID. N0:30 R08 CACACGGAACACCCTGTACTG SEQ. ID. NO:31 R54 CACCCTAAACACCCTATATTG SEQ. ID. NO:32 R85 AACCCGAAACACTCGATACTG 40 Probe sequences SEQ.ID.NO:33 HPV6B3: GGGT C ATCCTT ATTTTT CC AT A A SEQ.ID.NO:34 HPVl 1B2: GGGACATCCATATTACTCTATCAAA WO 2007/057669 PCT/GB2006/004266 48 10 15 20 25 30 35 40 seq.id.no seq.id.no seq.id.no: seq.id.no seq.id.no seq.id.no seq.id.no seq.id.no seq.id.no seq.id.no seq.id.no seq.id.no seq.id.no seq.id.no seq.id.no seq.id.no seq.id.no seq.id.no 35 HPV42B2: GGTCACCCTTATTACTCTATTACAAAA 36 HPV43B2: CACCCATATTTCCCCCTTAAA 37 HPV44/55B2: ACGACCAGCAAACAAGACAC 38 HPV16B5 39 HPV18B8 40HPV31B5 41 HPV33B7 42 HPV35B2 43 HPV39B3 44 HPV45B3 45 HPV51B2 :46 HPV52B2 :47 HPV56B2 :48 HPV58B2 :49 HPV59B2 50 HPV66B2 :51 HPV68B2 :52 HPV-ICB2: CAATAACAAAATATTAGTTCCTAAA TATCCTGCTTATTGCCACC CATACCTAAATCTGACAATCC TTTTTTAGCGTTAGTAGGATTTTT AAAACAAGATTCTAATAAAATAGCA TTAAAGTGGGTATGAATGGTTG GCTGTTCCTAAGGTATCCG AGC ACGCGTT GAGGTTTT A AGTTTT AGTTCCC A AGGT GT C CTGTGACTAAGGACAATACCAAA TTCCATCAAAAGTCCCAATAAC AAAGGTGGTAATGGTAGACAGG AATCTGGTACCAAAACAAACATC TTAAGGTTCCTATGTCTGGGG TGACATAGATCCCCATAGACAGTT SEQ.ID.NO:53 >Hpv2a cgga ctaatgtgta ttaccatggt ggcagttcta ggcttctcac tgtgggtcat ccatattact ctataaagaa gagtaataat aaggtggctg tgcccaaggt atctgggtac caatatcgtg tatttcacgt g SEQ.ID.NO:54 >HPV3 cgc accaacattt attattatgc aggcagttct cgcttgctga ccgtgggtca tccttatttt gctatcccca aatcttctaa ttccaagatg gatattccta aggtgtccgc ctttcaatat agagtgttta gggtg SEQ.ID.NO:55 >HPV6 cgcacca acatatttta tcatgccagc agttctagac ttcttgcagt gggtcatcct tatttttcca taaaacgggc taacaaaact gttgtgccaa aggtgtcagg atatcaatac agggtattta aggtg SEQ.ID.NO:56 >hpvl1 cgcacc aacatatttt atcatgccag cagttctaga ctccttgctg tgggacatcc atattactct atcaaaaaag ttaacaaaac agttgtacca aaggtgtctg gatatcaata tagagtgttt aaggta SEQ.ID.NO:57 >HPV13 cgtac caacatattt tatcatgcta gcagttctag actacttgca gtgggaaatc cttattttcc tattaagaaa caaaacaaaa ctgttgtccc taaggtatct ggttatcagt ttagggtatt taaagtt WO 2007/057669 PCT/GB2006/004266 49 SEQ.ID.NO:58 >HPV16 cgcacaa acatatatta tcatgcagga acatccagac tacttgcagt tggacatccc tattttccta 5 ttaaaaaacc taacaataac aaaatattag ttcctaaagt atcaggatta caatacaggg tatttagaat a SEQ.ID.NO:59 >HPV18 c ccacaagcat attttatcat gctggcagct ctagattatt aactgttggt aatccatatt ttagggttcc 10 tgcaggtggt ggcaataagc aggatattcc taaggtttct gcataccaat atagagtatt tagggtg SEQ.ID.NO:60 >HPV26 cgcacc ggcatatatt attatgcggg cagctctcgt ttattaacat taggacatcc atatttttcc 15 atacctaaaa ctggccaaaa ggccgaaatt cctaaggtat ctgcctatca gtacagggta tttagagtg SEQ.ID .NO:61 >HPV27 cggacgaatg tctattacca tggtggcagt tctaggctcc tcactgtcgg ccacccatat tattctataa 20 agaagggtag caataatagg ttggcagtgc ctaaggtgtc cggctaccaa taccgtgtat ttcacgtt SEQ.ID.NO:62 >HPV28 cgca ccaatattta ttattatgca ggcacttctc ggttgctgac cgtgggtcat ccttattttc ccattcctaa 25 atcatccact aacaaagcag atgtgcccaa agtgtccgcc tttcagtata gggtattccg ggtg SEQ.ID.NO:63 >HPV29 c gcacaaatat ttattattat gcaggcagtt ctcgcctgct cactgtgggt catccacatt attcaattcc 30 caaatcctct ggtaataagg tagatgtgcc taaggtgtct gcatttcagt acagggtttt ccgtgtg SEQ.ID.NO :64 >HPV30 eg caccaatata ttttatcatg caggcagctc aegtttgett gctgttggac atccatatta ttctatttct 35 aaggctggta attccaaaac agatgttccc aaggtgtctg catttcagta tagggtcttt agggtc SEQ.ID.NO-.65 >HPV31 eg aaccaacata tattatcacg caggcagtgc taggctgctt acagtaggcc atccatatta 40 ttccatacct aaatctgaca atcctaaaaa aatagttgta ccaaaggtgt caggattaca atatagggta tttagggtt SEQ.ID .NO:66 >HPV33 WO 2007/057669 PCT/GB2006/004266 50 cgcacaagca tttattatta tgctggtagt tccagacttc ttgctgttgg ccatccatat ttttctatta aaatcctac taacgctaaa aaattattgg tacccaaagt atcaggcttg caatataggg tttttagggt c SEQ.ID.NO:67 5 >HPV34 eg cacaaatata tattattatg caggtagtac acgcttgctg gcagtaggac atccctatta tcctataaag gatactaatg ggaaacgtaa gattgctgta cctaaagttt caggtttgca atacagggta tttagaata SEQ.ID.NO:68 10 >HPY35 cgcacaaaca tctactatca tgcaggcagt tctaggctat tagctgtggg tcacccatac tatgetatta aaaaacaaga ttctaataaa atagcagtac ccaaggtatc tggtttgcaa tacagagtat ttagagt SEQ.ID.NO:69 15 >HPV39 c gcacaggcat atattattat gctggcagct ctagattatt aacagtagga catccatatt ttaaagtggg tatgaatggt ggtcgcaagc aggacattcc aaaggtgtct gcatatcaat atagggtatt tegegtg SEQ.ID.NO:70 20 >HPV40 cgcaccag tttatattat catgctggta gtgccaggtt actgactata ggacatccat actttgagtt aaaaaaaccc aatggtgaca tttcagtgcc taaggtttct ggacatcaat acagggtatt tagggta SEQ.ID ,N0:71 25 >HPV42 cgcacca actactttta ccatgccagc agttctaggc tattggttgt tggtcaccct tattactcta ttacaaaaag gccaaataag acatctatcc ccaaagtgtc tggtttacag tacagagtat ttagagtt SEQ.ID.NO:72 30 >HPV43 cgcaccaact tattttatta tgctggcagt tcacgtttgc ttgcagtggg tcacccatat ttccccctta aaaattcctc tggtaaaata actgtaccta aggtttctgg ttatcaatac agagtattta gagtt SEQ.ID.NO:73 35 >HPV44 cgc accaacatat attaccatgc tagcagttct agacttcttg ctgtgggcaa cccttatttt gccatacgac cagcaaacaa gacacttgtg cctaaggttt egggatttea atatagggtt tttaagatg SEQ.ID .NO:74 40 >HPV45 cgcaca agcatatttt ateatgeagg cagttcccga ttattaactg taggcaatcc atattttagg gttgtaccta atggtgcagg taataaacag gctgttccta aggtatccgc atatcagtat agggtgttta gagta WO 2007/057669 PCT/GB2006/004266 51 SEQ.ID .NO:75 >HPV51 cgc accggcatat attactatgc aggcagttcc agactaataa cattaggaca tccctatttt ccaataccta aaacctcaac gcgtgctgct attcctaaag tatctgcatt tcaatacagg gtatttaggg ta 5 SEQ.ID.NO:76 >HPV52 c gcacaagcat ctattattat gcaggcagtt ctcgattact aacagtagga catccctatt tttctattaa aaacaccagt agtggtaatg gtaaaaaagt tttagttccc aaggtgtctg gcctgcaata cagggtattt 10 agaatt SEQ.ID.NO:77 >HPV53 cgcaccact atattttatc atgctggaag ctctcgcttg cttaccgtgg gacatcctta ttaccccatt 15 tctaaatctg gtaaagcaga catccctaag gtgtctgcat ttcagtatag ggtgtttaga gta SEQ.ID.NO:78 >HPV54 cgcaca agcatatact atcatgcaag cagctctaga ttattggctg ttggacatcc atattttaaa 20 gtacaaaaaa ccaataataa gcaaagtatt cctaaagtat caggatatca atatagggtg tttagggtg SEQ.ID.NO:79 >HPV55 cgc accaacatag tttaccatgc tagcagttct agacttcttg ctgtaggcaa cccttatttt gccatacgac 25 cagcaaacaa gacacttgtg cctaaagttt caggatttca atatagggtt tttaaggtg SEQ.ID.NO:80 >HPV56 cgcacta gtatatttta tcatgcaggc agttcacgat tgcttgccgt aggacatccc tattactctg 30 tgactaagga caataccaaa acaaacattc ccaaagttag tgcatatcaa tatagggtat ttagggta SEQ.ID.NO :81>HPV57 egg acgaatgttt attatcatgg tgggagctct cggctcctca cagtaggcca tccatattat tctataaaaa aaagtggcaa taataaggtg tctgtgccca aggtateggg ctaccagtac cgtgtgttcc atgtg 35 SEQ.ID.NO-.82 >HPY58 c gcacaagcat ttattattat gctggcagtt ccagactttt ggctgttggc aatccatatt tttccatcaa aagtcccaat aacaataaaa aagtattagt tcccaaggta tcaggcttac agtatagggt ctttagggtg 40 SEQ.ID.NO-.83 >HPV59 cgtaccag tattttctac cacgcaggca gttccagact tcttacagtt ggacatccat attttaaagt acctaaaggt ggtaatggta gacaggatgt tcctaaggtg tetgeatate aatacagagt atttagggtt WO 2007/057669 PCT/GB2006/004266 52 SEQ.ID.NO:84 >HPV61 cgcaccaact tattttatta tggtggcagt tcccgtctgc ttactgtagg acatccctat tgtagtttgc 5 agcttgatgg gctgcagggc aagaaaaaca ctatccccaa ggtgtctggc tatcaatata gggtgtttag ggta SEQ.ID.NO:85 10 >HPV62 cgcacca acctttttta ttatgggggc agctcccgcc ttcttactgt gggacatcca tattgtactt tacaggttgg ccagggtaaa cgggccacca ttcctaaggt gtctgggtat cagtacaggg tgtttcgtgt g 15 SEQ.ID.NO: 86 >HPV66 cgtacca gtatatttta tcatgcaggt agctctaggt tgcttgctgt tggccatcct tattactctg tttccaaatc tggtaccaaa acaaacatcc ctaaagttag tgcatatcag tatagagtgt ttagggta 20 SEQ.ID.NO:87 >HPV67 cgcacaag catttactat tacgctggta gctccagact tttagctgta ggccatcctt acttttccat tcctaatccc tccaacacta aaaaggtgtt agtgcccaag gtgtcaggtt tgcagtatag ggtatttagg gtt 25 SEQ.ID.NO:88 >HPV68 cgcactggca tgtattacta tgctggtaca tctaggttat taactgtagg ccatccatat tttaaggttc ctatgtctgg gggccgcaag cagggcattc ctaaggtgtc tgcatatcaa tacagagtgt ttagggtt 30 SEQ.ID.NO:89 >HPV69 cgcac cggatatatt actatgcagg cagctctcga ttattaactt tgggtcatcc ctattttcca attcctaaat 35 ctggttcaac agcagaaatt cctaaagtgt ctgcttacca atatagggtt tttcgtgtt SEQ.ID .NO: 90 >HPV70 cgta caggcatata ttattatgct ggaagctctc gcttattaac agtagggcat ccttatttta aggtacctgt 40 aaatggtggc cgcaagcagg aaatacctaa ggtgtctgca tatcagtata gggtatttag ggta SEQ.ID.NO:91 >HPV72 WO 2007/057669 PCT/GB2006/004266 53 cgcacca acctctatta ttatggtggc agttctcgtc tactaactgt aggacatcct tactgtgcca tacctctcaa cggacagggc aaaaaaaaca ccattcctaa ggtttcgggg tatcaataca gggtgtttag agta 5 SEQ.ID.NO:92 >HPV73 agaaca aatatatatt attatgcagg tagcacacgt ttgttggctg tgggacaccc atattttcct atcaaggatt ctcaaaaacg taaaaccata gttcctaaag tttcaggttt gcaatacagg gtgtttaggc tt 10 SEQ.ID.NO :93 >HPV74 cgcacc aacatctttt atcatgctag cagttctaga ctacttgctg taggaaatcc ctatttccct ataaaacagg ttaacaaaac agttgttcct aaagtgtctg gatatcaatt tagggtgttt aaggtg 15 SEQ.ID.NO:94 >HPV81 cgcacc aacctttttt attatggggg cagttcccgc cttcttactg tagggcatcc atattgtaca ttaactattg gtacccaagg aaagcgttcc actattccca aggtgtctgg gtatcagtac cgggtgtttc gtgtg 20 SEQ.ID.NO :95 >HPV82 cgc accggcatat attattatgc aggcagttcc agacttatta ccttaggaca tccatatttt tcaataccca aaaccaatac acgtgctgaa atacctaagg tatctgcctt tcagtatagg gtgtttaggg ta 25 SEQ.ID .NO:96 >HPV83 eg caccaacctc ttttattacg gtggcagctc cagacttctt accgtaggac atccatatta tcctgtacag gttaatggtc aaggaaaaaa agccactatc cccaaggttt ctggctacca atatagggtg tttcgcatt 30 SEQ.ID.NO:97 >HPV84 cgcaccaac ttattttatt atggtggtag ttctcgcctg cttactgtgg gacatccata ttattctgtt cctgtgtcta cccctgggca aaacaacaaa aaggccacta tccccaaggt ttctgggtat caatacaggg tgtttagggt c 35 SEQ.ED.NO:98 >HPV85 cgta ccagtacatt ttatcatgct ggcagctcta ggcttctaac cgttggacat ccatactata aagttacctc aaatggaggc cgcaagcaag acattcctaa agtgtctgcc tatcagtatc gagtgtttcg ggtt 40 SEQ.ID.NO:99 >HPY86 cgtaccaac ctattttatt atggtggtag ttcccgcttg cttactgtgg gccatccata ttatcctgtt actgtttcct ccagccctgg acaaaacaac aaaaaggcca atattcccaa ggtttcgggg tatcaataca </div>

Claims

<div class="application article clearfix printTableText" id="claims"> WO 2007/057669 PCT/GB2006/004266 54 gggtttttag ggtg SEQ.ID.NO: 100 >HPV87 5 cgcaccaac ttattttatt atggtggcag ttctcgcctg cttactgtgg gtcaccctta ctatccagtt actgttacca cccctggtca gaacaagaaa tccaatattc caaaggtgtc tggctatcag tacagggtgt ttcgggtg SEQ.ID.NO: 101 10 >HPV89 cgtaccaac ctgtactatt atggaggcag ctcccgcctt attacagttg gccaccctta ttatactgta caggtcaatg gtgctaacaa aaaggccaac atacctaagg tatcagggta tcaatacagg gtatttaggg ta 15 SEQ.ID.NO: 102 >HPV90 agaacaaacata tattattatg caggcagttc ccgactgtta actgttggcc atccttattt tgctatcaaa aagcaatcag gaaaaaaccc tatagtggtt cccaaggtgt ctggatatca atatagggtg tttagggta 20 SEQ.ID.NO: 103 >HPV91 cgcacc aacttatttt accatgctgg cagttcccgt ttactggctg tgggccaccc tttttttcct ataaaaaata attctggtaa agtaattgtt cctaaagttt caggtcacca atatagggtg tttagagtt 25 SEQ.ID.NO: 104 HPV-IC CGGACGAATGTTTATTACCAGATAGATAGAGATAGATACCCATATA CAGATAATGACATAGATCCCCATAGACAGTTTATACAGATCAGTAG CAGTTTTTATATATGAGATGATGATAGCAATACAGAGTATTTAGGGT 30 A SEQ.ID.NO: 105 HPV11B3/2: A A A ACAGTT GT ACC A A AGGT GT CT G SEQ.ID.NO: 106 HPV42B1: CAAAAAGGCCAAATAAGACA SEQ.ID.NO: 107 HPV43B6: CCCCCTTAAAAATTCCTCT 35 SEQ.ID .N0:108 HPV44/55B1 ATACGACCAGCAAACAAGAC SEQ.ID.NO:109 HPV39B4: TATGAATGGTGGTCGCAAG SEQ.ID.NO: 110 HPV52B7: AAAACACCAGTAGTGCTAATG SEQ.ID.NO:l 11 HPV56B3: CCAAAACAAACATTCCCAA SEQ.ID.NO:l 12 HPV59B3: ATCCATATTTTAAAGTACCTAAAG 40 SEQ.ID.NO:113 HPV66B1: CAAATCTGGTACCAAAACAAA SEQ.ID.NO: 114 HPV-ICB4: CCCATAGACAGTTTATACAGATCA SEQ.ID.NO-.115 HPV6B6: ATAAAACGGGCTAACAAAA SEQ.ID .NO:l 16 HPV26B1: T ACCT A A A ACT GGCC A A AAG SEQ.ID.NO:l 17 HPV35B4: ATTCTAATAAAATAGCAGTACCCAAG 55 Received at IPONZ on 13 July 2011 WHAT WE CLAIM IS:

1. A method of detecting the presence of at least one pathogen comprising contacting a nucleic acid obtained from a sample with a set comprising at least four probes wherein each of said probes comprises a sequence complementary to a sequence from a pathogen flanked by four pairs of complementary bases, wherein said bases form a stem structure in the absence of hybridization to a nucleic acid from pathogen, wherein said probe is labeled with a first interacting label and a second interacting label such that hybridizing of said probe to a nucleic acid from said pathogen causes a change in the signal detected.

2. The method as claimed in claim 1 wherein said first interacting label and said second interacting label are a FRET donor and FRET acceptor.

3. The method as claimed in claim 2 wherein said FRET acceptor is a quencher.

4. The method as claimed in any one of claims 1 to 3 wherein said sequence complementary to a sequence from a pathogen is connected to said pair(s) of complementary bases at either end by linking sequences

5. The method as claimed in any one of claims 1 to 4 wherein said pairs of complementary bases comprise C-G pairs. .

6. The method as claimed in claim 5 wherein said probe comprises the sequence 3' - CGCG-F- sequence unique to pathogen -F' - CGCG -5' wherein F and F' are optional linking sequences. 1108535v1 56 Received at IPONZ on 13 July 2011

7. The method as claimed in any one of claims 1 to 6 wherein the sequence unique to the pathogen within the probe contains at least one mismatch with the genomic sequence of the pathogen.

8. The method as claimed in any one of claims 1 to 7 wherein each of said probes can be distinguished from each of the other said probes.

9. The method as claimed in any one of claims 1 to 8 wherein each of said probes is attached to a solid support at a defined location

10. The method as claimed in any one of claims 1 to 9 wherein said set of probes comprises at least 10, at least 15 or at least 20 probes.

11. The method as claimed in any one of claims 1 to 10 wherein said method further comprises determining the melting temperature of the double stranded nucleic acid molecule formed by one of said probes and complementary nucleic acid obtained from said sample.

12. The method as claimed in any one of claims 1 to 11 wherein said nucleic acid obtained from a sample is amplified prior to being contacted with said set of probes.

13. The method as claimed in claim 12 wherein said amplification is carried out utilizing the polymerase chain reaction (PCR).

14. The method of claim 12 or claim 13 wherein the production of amplified nucleic acid is monitored continuously.

15. The method as claimed in any one of claims 12 to 15 wherein said amplified nucleic acid is contacted with said set of probes after one cycle of amplification. 1108535v1 57 Received at IPONZ on 13 July 2011

16. The method as claimed in any one of claims 12 to 15 wherein said amplified nucleic acid is contacted with said set of probes after each amplification cycle.

17. The method as claimed in any one of claims 12 to 16 wherein said amplification is carried out in the presence of said set of probes.

18. The method as claimed in any one of claims 12 to 17 wherein said method further comprises amplification of an internal control.

19 The method as claimed in any one of claims 12 to 18 wherein amplification of contaminant nucleic acid is prevented.

20. The method as claimed in claim 19 wherein said amplification of contaminant nucleic acid is prevented by performing the amplification in the presence of uracil.

21. The method as claimed in claim 20 further comprising treating said nucleic acid with uracil-DNA glycosylase prior to amplification.

22. The method as claimed in any one of claims 1 to 21 wherein said sample is selected from bronchial aspirates, urine, prostata massate, ejaculatum, blood and cervical, vulvar, anal, genital, skin or laryngeal cytological samples, scrapings or biopsies.

23. The method as claimed in any one of claims 1 to 22 for detecting an organism asociated with a sexually transmitted disease. 1108535v1 58 Received at IPONZ on 13 July 2011

24. The method as claimed in any one of claims 1 to 23 for detecting the presence of at least one HPV genotype

25. The method as claimed in claim 24 for detecting high risk or low risk HPV genotypes.

26. The method as claimed in claim 24 or claim 25 wherein said set of probes comprises at least one probe comprising at least one of the sequences selected from SEQ ID Nos. 33 to 52 or SEQ ID Nos. 105-117.

27. The method as claimed in any one of claims 24 to 26 wherein said nucleic acid obtained from said sample is amplified utilising at least one primer selected from Seq ID. Nos. 1 to 32.

28. The method as claimed in claim 27 wherein nucleic acid obtained from said sample is amplified utilising a primer mixture comprising Seq ID. Nos. 1 to 32.

29. A set of probes comprising at least four probes wherein each of said probes comprises a sequence complementary to a sequence from a pathogen flanked by four pairs of complementary bases, wherein said bases form a stem structure in the absence of hybridization to a nucleic acid from a pathogen, wherein said probe is labeled with a first interacting label and a second interacting label such that hybridizing of said probe to a nucleic acid from said pathogen causes a change in the signal detected.

30. The set of probes as claimed in claim 29 wherein said first interacting label and said second interacting label are a FRET donor and FRET acceptor.

31. The set of probes as claimed in claim 30 wherein said FRET acceptor is a quencher. 1108535v1 59 Received at IPONZ on 13 July 2011

32. The set of probes as claimed in any one of claims 29 to 31 wherein said sequence complementary to a sequence from a pathogen is connected to said pair(s) of complementary bases at either end by linking sequences.

33. The set of probes as claimed in any one of claims 29 to 32 wherein said pairs of complementary bases comprise C-G pairs.

34. The set of probes as claimed in claim 33 wherein each of said probes comprises the sequence 3' - CGCG-F- sequence unique to pathogen -F' - CGCG -5' wherein F and F' are optional linking sequences.

35. The set of probes as claimed in any one of claims 29 to 34 wherein the sequence unique to the pathogen within the probe contains at least one mismatch with the genomic sequence of the pathogen.

36. The set of probes as claimed in any one of claims 29 to 35 wherein each of said probes can be distinguished from each of the other said probes.

37. The set of probes as claimed in any one of claims 29 to 36 wherein each of said probes is attached to a solid support at a defined location.

38. The set of probes as claimed in any one of claims 29 to 37 wherein said pathogen an organism associated with a sexually transmitted disease.

39. The set of probes as claimed in claim 38 wherein said organism is a virus.

40. The set of probes as claimed in claim 39 wherein said virus is human pappillomavirus. 1108535v1 60 Received at IPONZ on 13 July 2011

41. The set of probes as claimed in claim 40 wherein each of said probes comprises a sequence which is complementary to an HPV genotype.

42. The set of probes as claimed in claim 41 wherein said each of said probes comprises a sequence which is complementary to a high risk HPV genotype.

43. The set of probes as claimed in claim 41 wherein said each of said probes comprises a sequence which is complementary to a low risk HPV genotype.

44. The set of probes as claimed in any one of claims 40 to 43 wherein said set of probes comprises at least one probe comprising at least one of the sequences selected from SEQ ID Nos. 33 to 52 or SEQ ID Nos. 105-117.

45. The set of probes of claim 44 wherein each probe of said set of probes comprises a sequence selected from SEQ ID Nos. 33 to 52 or SEQ ID Nos 105-117.

46. The set of probes of claim 44 or claim 45 wherein each probe of said set of probes comprises a sequence selected from SEQ ID Nos. 33 to 52.

47. A kit for detecting one or more pathogens comprising a set of probes as claimed in any one of claims 29 to 46.

48. A kit as claimed in claim 47 wherein said pathogen is an organism associated with a sexually transmitted disease

49. A kit for detecting one or more HPV genotypes comprising a set of probes as claimed in any one of claims 29 to 46. 1108535v1 Received at IPONZ on 03 November 2011 61

50. The kit as claimed in any one of claims 47 to 49 further comprising an internal control.

51. The method of claim 13, additionally comprising the step of heating to about 55°c for about 5 minutes prior to amplification.

52. A method as claimed in any one of claims 1 to 28 and 51 of detecting the presence of at least one pathogen, substantially as herein described with reference to any example thereof.

53. A set of probes as claimed in any one of claims 29 to 46, substantially as herein described with reference to any example thereof.

54. A kit as claimed in any one of claims 47 to 50, substantially as herein described with reference to any example thereof. 1108535v1 WO 2007/057669 PCT/GB2006/004266 P38434WO Genoid.ST25 SEQUENCE LISTING <110> Genoi d Kft Jeney, Csaba Hart, Deborah M Takacs, Tibor <120> Method <130> P38434WO <150> US 60/737006 <151> 2005-11-15 <150> GB 0523250.9 <151> 2005-11-15 <160> 117 <170> Patentin version 3.3 <210> 1 <211> 19 <212> DNA <213> Artificial <220> <223> Primer <400> 1 cgcaccaaca tattttatt 19 <210> 2 <211> 20 <212> DNA <213> Artificial <220> <223> Primer <400> 2 cgcacaagca tctattatta 20 <210> 3 <211> 19 <212> DNA <213> Artificial <220> <223> Primer <400> 3 cgcacaagca tattttatc 19 <210> 4 <211> 20 <212> DNA <213> Artificial <220> Page 1 WO 2007/057669 PCT/GB2006/004266 P38434WO Genoid.ST25 <223> Primer <400> 4 cgcaccagta tattttatca 20 <210> 5 <211> 20 <212> DNA <213> Artificial <220> <223> Primer <400> 5 cgcacaagca tttactatca 20 <210> 6 <211> 19 <212> DNA <213> Artificial <220> <223> Primer <210> 7 <211> 21 <212> DNA <213> Artificial <220> <223> Primer <400> 7 cgtaccagta ttttctacca c 21 <210> 8 <211> 19 <212> DNA <213> Artificial <220> <223> Primer <210> 9 <211> 20 <212> DNA <213> Artificial <220> <223> Primer <400> 6 cgcaccaact acttttacc 19 <400> 8 cgcacaggca tatattact 19 <400> 9 Page 2 WO 2007/057669 PCT/GB2006/004266 P38434WO Genoid.ST25 cgcaccaaca tatattatca 20 <210> 10 <211> 22 <212> DNA <213> Artificial <220> <223> Primer <400> 10 cgtaccaacc tgtactatta tg 22 <210> 11 <211> 20 <212> DNA <213> Artificial <220> <223> Primer <210> 12 <211> 20 <212> DNA <213> Artificial <220> <223> Primer <400> 12 accaacctct tttattatgg 20 <210> 13 <211> 23 <212> DNA <213> Artificial <220> <223> Primer <210> 14 <211> 18 <212> DNA <213> Artificial <220> <223> Primer <400> 14 cgcaccggat atattact 18 <400> 11 gcaccaactt attttaccat 20 <400> 13 agcacaaata tatattatta tgg 23 Page 3 WO 2007/057669 PCT/GB2006/004266 <210> 15 <211> 23 <212> DNA <213> Artificial <220> <223> Primer <400> 15 cgcacaaata tttattatta tgc <210> 16 <211> 19 <212> DNA <213> Artificial <220> <223> Primer <400> 16 cggacgaatg tttattacc <210> 17 <211> 21 <212> DNA <213> Artificial <220> <223> Primer <400> 17 taccctaaat actctgtatt g <210> 18 <211> 21 <212> DNA <213> Arti fi ci al <220> <223> Primer <400> 18 taccctaaat accctatatt g <210> 19 <211> 21 <212> DNA <213> Artificial <220> <223> Primer <400> 19 aattctaaaa actctgtact g <210> 20 <211> 21 <212> DNA P38434WO Genoid.ST25 23 19 21 21 21 Page 4 WO 2007/057669 PCT/GB2006/004266 <213> Artificial <220> <223> Primer <400> 20 tactctaaat actctgtatt g <210> 21 <211> 21 <212> DNA <213> Artificial <220> <223> Primer <400> 21 taccttaaac actctatatt g <210> 22 <211> 21 <212> DNA <213> Artificial <220> <223> Primer <400> 22 tattctaaat accctgtatt g <210> 23 <211> 21 <212> DNA <213> Artificial <220> <223> Primer <400> 23 aactctaaat actctgtact g <210> 24 <211> 21 <212> DNA <213> Artificial <220> <223> Primer <400> 24 catcttaaaa accctatatt g <210> 25 <211> 21 <212> DNA <213> Artificial <220> P38434WO Genoid.ST25 21 21 21 21 21 Page 5 WO 2007/057669 PCT/GB2006/004266 P38434WO Genoid.ST25 <223> Primer <400> 25 aaccctaaac accctgtatt g 21 <210> 26 <211> 21 <212> DNA <213> Artificial <220> <223> Primer <400> 26 aacgcgaaaa accctatatt g 21 <210> 27 <211> 21 <212> DNA <213> Artificial <220> <223> Primer <400> 27 taccctaaag accctatact g 21 <210> 28 <211> 21 <212> DNA <213> Artificial <220> <223> Primer <400> 28 aactctaaat accctatact g 21 <210> 29 <211> 21 <212> DNA <213> Artificial <220> <223> Primer <400> 29 aacgtgaaat acacgatatt g 21 <210> 30 <211> 21 <212> DNA <213> Artificial <220> <223> Primer <400> 30 Page 6 WO 2007/057669 PCT/GB2006/004266 P38434WO Genoid.ST25 cacacggaac accctgtact g 21 <210> 31 <211> 21 <212> DNA <213> Artificial <220> <223> Primer <400> 31 caccctaaac accctatatt g 21 <210> 32 <211> 21 <212> DNA <213> Artificial <220> <223> Primer <210> 33 <211> 23 <212> DNA <213> Arti fi ci al <220> <223> Probe <400> 33 gggtcatcct tatttttcca taa 23 <210> 34 <211> 25 <212> DNA <213> Artificial <220> <223> Probe <210> 35 <211> 27 <212> DNA <213> Artificial <220> <223> Probe <400> 35 ggtcaccctt attactctat tacaaaa 27 <400> 32 aacccgaaac actcgatact g 21 <400> 34 gggacatcca tattactcta tcaaa 25 Page 7 WO 2007/057669 PCT/GB2006/004266 P38434WO Genoid.ST25 <210> 36 <211> 21 <212> DNA <213> Artificial <220> <223> Probe <400> 36 cacccatatt tcccccttaa a 21 <210> 37 <211> 20 <212> DNA <213> Artificial <220> <223> Probe <400> 37 acgaccagca aacaagacac 20 <210> 38 <211> 25 <212> DNA <213> Artificial <220> <223> Probe <400> 38 caataacaaa atattagttc ctaaa 25 <210> 39 <211> 19 <212> DNA <213> Artificial <220> <223> Probe <400> 39 tatcctgctt attgccacc 19 <210> 40 <211> 21 <212> DNA <213> Artificial <220> <223> Probe <400> 40 catacctaaa tctgacaatc c 21 <210> 41 <211> 24 <212> DNA Page 8 WO 2007/057669 PCT/GB2006/004266 <213> Artificial P38434WO Genoid.ST25 <220> <223> Probe <400> 41 ttttttagcg ttagtaggat tttt 24 <210> 42 <211> 25 <212> DNA <213> Artificial <220> <223> Probe <400> 42 aaaacaagat tctaataaaa tagca 25 <210> 43 <211> 22 <212> DNA <213> Artificial <220> <223> Probe <210> 44 <211> 19 <212> DNA <213> Artificial <220> <223> Probe <400> 44 gctgttccta aggtatccg 19 <210> 45 <211> 19 <212> DNA <213> Artificial <220> <223> Probe <210> 46 <211> 21 <212> DNA <213> Artificial <220> <400> 43 ttaaagtggg tatgaatggt tg 22 <400> 45 agcacgcgtt gaggtttta 19 Page 9 WO 2007/057669 PCT/GB2006/004266 P38434WO Genoid.ST25 <223> Probe <400> 46 agttttagtt cccaaggtgt c 21 <210> 47 <211> 23 <212> DNA <213> Artificial <220> <223> Probe <400> 47 ctgtgactaa ggacaatacc aaa 23 <210> 48 <211> 22 <212> DNA <213> Artificial <220> <223> Probe <210> 49 <211> 22 <212> DNA <213> Artificial <220> <223> Probe <400> 49 aaaggtggta atggtagaca gg 22 <210> 50 <211> 23 <212> DNA <213> Artificial <220> <223> Probe <210> 51 <211> 21 <212> DNA <213> Artificial <220> <223> Probe <400> 51 <400> 48 ttccatcaaa agtcccaata ac 22 <400> 50 aatctggtac caaaacaaac ate 23 Page 10 WO 2007/057669 PCT/GB2006/004266 P38434WO Genoid.ST25 ttaaggttcc tatgtctggg g 21 <210> 52 <211> 24 <212> DNA <213> Artificial <220> <223> Probe <400> 52 tgacatagat ccccatagac agtt 24 <210> 53 <211> 135 <212> DNA <213> Hpv2a <400> 53 cggactaatg tgtattacca tggtggcagt tctaggcttc tcactgtggg tcatccatat 60 tactctataa agaagagtaa taataaggtg gctgtgccca aggtatctgg gtaccaatat 120 cgtgtatttc acgtg 135 <210> 54 <211> 138 <212> DNA <213> HPV3. <400> 54 cgcaccaaca tttattatta tgcaggcagt tctcgcttgc tgaccgtggg tcatccttat 60 tttgctatcc ccaaatcttc taattccaag atggatattc ctaaggtgtc cgcctttcaa 120 tatagagtgt ttagggtg 138 <210> 55 <211> 132 <212> DNA <213> HPV6 <400> 55 cgcaccaaca tattttatca tgccagcagt tctagacttc ttgcagtggg tcatccttat 60 ttttccataa aacgggctaa caaaactgtt gtgccaaagg tgtcaggata tcaatacagg 120 gtatttaagg tg 132 <210> 56 <211> 132 <212> DNA <213> hpvll <400> 56 cgcaccaaca tattttatca tgccagcagt tctagactcc ttgctgtggg acatccatat 60 tactctatca aaaaagttaa caaaacagtt gtaccaaagg tgtctggata tcaatataga 120 Page 11 WO 2007/057669 PCT/GB2006/004266 P38434WO Genoid.ST25 gtgtttaagg ta 132 <210> 57 <211> 132 <212> DNA <213> HPV13 <400> 57 cgtaccaaca tattttatca tgctagcagt tctagactac ttgcagtggg aaatccttat 60 tttcctatta agaaacaaaa caaaactgtt gtccctaagg tatctggtta tcagtttagg 120 gtatttaaag tt 132 <210> 58 <211> 138 <212> DNA <213> HPV16 <400> 58 cgcacaaaca tatattatca tgcaggaaca tccagactac ttgcagttgg acatccctat 60 tttcctatta aaaaacctaa caataacaaa atattagttc ctaaagtatc aggattacaa 120 tacagggtat ttagaata 138 <210> 59 <211> 138 <212> DNA <213> HPV18 <400> 59 cccacaagca tattttatca tgctggcagc tctagattat taactgttgg taatccatat 60 tttagggttc ctgcaggtgg tggcaataag caggatattc ctaaggtttc tgcataccaa 120 tatagagtat ttagggtg 138 <210> 60 <211> 135 <212> DNA <213> HPV26 <400> 60 cgcaccggca tatattatta tgcgggcagc tctcgtttat taacattagg acatccatat 60 ttttccatac ctaaaactgg ccaaaaggcc gaaattccta aggtatctgc ctatcagtac 120 agggtattta gagtg 135 <210> 61 <211> 138 <212> DNA <213> HPV27 <400> 61 cggacgaatg tctattacca tggtggcagt tctaggctcc tcactgtcgg ccacccatat 60 Page 12 WO 2007/057669 PCT/GB2006/004266 P38434WO Genoid.ST25 tattctataa agaagggtag caataatagg ttggcagtgc ctaaggtgtc cggctaccaa 120 taccgtgtat ttcacgtt 138 <210> 62 <211> 138 <212> DNA <213> HPV28 <400> 62 cgcaccaata tttattatta tgcaggcact tctcggttgc tgaccgtggg tcatccttat 60 tttcccattc ctaaatcatc cactaacaaa gcagatgtgc ccaaagtgtc cgcctttcag 120 tatagggtat tccgggtg 138 <210> 63 <211> 138 <212> DNA <213> HPV29 <400> 63 cgcacaaata tttattatta tgcaggcagt tctcgcctgc tcactgtggg tcatccacat 60 tattcaattc ccaaatcctc tggtaataag gtagatgtgc ctaaggtgtc tgcatttcag 120 tacagggttt tccgtgtg 138 <210> 64 <211> 138 <212> DNA <213> HPV30 <400> 64 cgcaccaata tattttatca tgcaggcagc tcacgtttgc ttgctgttgg acatccatat 60 tattctattt ctaaggctgg taattccaaa acagatgttc ccaaggtgtc tgcatttcag 120 tatagggtct ttagggtc 138 <210> 65 <211> 141 <212> DNA <213> HPV31 <400> 65 cgaaccaaca tatattatca cgcaggcagt gctaggctgc ttacagtagg ccatccatat 60 tattccatac ctaaatctga caatcctaaa aaaatagttg taccaaaggt gtcaggatta 120 caatataggg tatttagggt t 141 <210> 66 <211> 140 <212> DNA <213> HPV33 Page 13 WO 2007/057669 PCT/GB2006/004266 P38434WO Genoid.ST25 <400> 66 cgcacaagca tttattatta tgctggtagt tccagacttc ttgctgttgg ccatccatat 60 ttttctatta aaatcctact aacgctaaaa aattattggt acccaaagta tcaggcttgc 120 aatatagggt ttttagggtc 140 <210> 67 <211> 141 <212> DNA <213> HPV34 <400> 67 cgcacaaata tatattatta tgcaggtagt acacgcttgc tggcagtagg acatccctat 60 tatcctataa aggatactaa tgggaaacgt aagattgctg tacctaaagt ttcaggtttg 120 caatacaggg tatttagaat a 141 <210> 68 <211> 137 <212> DNA <213> HPV35 <400> 68 cgcacaaaca tctactatca tgcaggcagt tctaggctat tagctgtggg tcacccatac 60 tatgctatta aaaaacaaga ttctaataaa atagcagtac ccaaggtatc tggtttgcaa 120 tacagagtat ttagagt 137 <210> 69 <211> 138 <212> DNA <213> HPV39 <400> 69 cgcacaggca tatattatta tgctggcagc tctagattat taacagtagg acatccatat 60 tttaaagtgg gtatgaatgg tggtcgcaag caggacattc caaaggtgtc tgcatatcaa 120 tatagggtat ttcgcgtg 138 <210> 70 <211> 135 <212> DNA <213> HPV40 <400> 70 cgcaccagtt tatattatca tgctggtagt gccaggttac tgactatagg acatccatac 60 tttgagttaa aaaaacccaa tggtgacatt tcagtgccta aggtttctgg acatcaatac 120 agggtattta gggta 135 <210> 71 <211> 135 <212> DNA Page 14 WO 2007/057669 PCT/GB2006/004266 P38434WO Genoid.ST25 <213> HPV42 <400> 71 cgcaccaact acttttacca tgccagcagt tctaggctat tggttgttgg tcacccttat 60 tactctatta caaaaaggcc aaataagaca tctatcccca aagtgtctgg tttacagtac 120 agagtattta gagtt 135 <210> 72 <211> 135 <212> DNA <213> HPV43 <400> 72 cgcaccaact tattttatta tgctggcagt tcacgtttgc ttgcagtggg tcacccatat 60 ttccccctta aaaattcctc tggtaaaata actgtaccta aggtttctgg ttatcaatac 120 agagtattta gagtt 135 <210> 73 <211> 132 <212> DNA <213> HPV44 <400> 73 cgcaccaaca tatattacca tgctagcagt tctagacttc ttgctgtggg caacccttat 60 tttgccatac gaccagcaaa caagacactt gtgcctaagg tttcgggatt tcaatatagg 120 gtttttaaga tg 132 <210> 74 <211> 141 <212> DNA <213> HPV45 <400> 74 cgcacaagca tattttatca tgcaggcagt tcccgattat taactgtagg caatccatat 60 tttagggttg tacctaatgg tgcaggtaat aaacaggctg ttcctaaggt atccgcatat 120 cagtataggg tgtttagagt a 141 <210> 75 <211> 135 <212> DNA <213> HPV51 <400> 75 cgcaccggca tatattacta tgcaggcagt tccagactaa taacattagg acatccctat 60 tttccaatac ctaaaacctc aacgcgtgct gctattccta aagtatctgc atttcaatac 120 agggtattta gggta 135 <210> 76 Page 15 WO 2007/057669 PCT/GB2006/004266 P38434WO Genoid.ST25 <211> 147 <212> DNA <213> HPV52 <400> 76 cgcacaagca tctattatta tgcaggcagt tctcgattac taacagtagg acatccctat 60 ttttctatta aaaacaccag tagtggtaat ggtaaaaaag ttttagttcc caaggtgtct 120 ggcctgcaat acagggtatt tagaatt 147 <210> 77 <211> 132 <212> DNA <213> HPV53 <400> 77 cgcaccacta tattttatca tgctggaagc tctcgcttgc ttaccgtggg acatccttat 60 taccccattt ctaaatctgg taaagcagac atccctaagg tgtctgcatt tcagtatagg 120 gtgtttagag ta 132 <210> 78 <211> 135 <212> DNA <213> HPV54 <400> 78 cgcacaagca tatactatca tgcaagcagc tctagattat tggctgttgg acatccatat 60 tttaaagtac aaaaaaccaa taataagcaa agtattccta aagtatcagg atatcaatat 120 agggtgttta gggtg 135 <210> 79 <211> 132 <212> DNA <213> HPV55 <400> 79 cgcaccaaca tagtttacca tgctagcagt tctagacttc ttgctgtagg caacccttat 60 tttgccatac gaccagcaaa caagacactt gtgcctaaag tttcaggatt tcaatatagg 120 gtttttaagg tg 132 <210> 80 <211> 135 <212> DNA <213> HPV56 <400> 80 cgcactagta tattttatca tgcaggcagt tcacgattgc ttgccgtagg acatccctat 60 tactctgtga ctaaggacaa taccaaaaca aacattccca aagttagtgc atatcaatat 120 agggtattta gggta 135 Page 16 WO 2007/057669 PCT/GB2006/004266 P38434WO Genoid.ST25 <210> 81 <211> 138 <212> DNA <213> HPV57 <400> 81 cggacgaatg tttattatca tggtgggagc tctcggctcc tcacagtagg ccatccatat 60 tattctataa aaaaaagtgg caataataag gtgtctgtgc ccaaggtatc gggctaccag 120 taccgtgtgt tccatgtg 138 <210> 82 <211> 141 <212> DNA <213> HPV58 <400> 82 cgcacaagca tttattatta tgctggcagt tccagacttt tggctgttgg caatccatat 60 ttttccatca aaagtcccaa taacaataaa aaagtattag ttcccaaggt atcaggctta 120 cagtataggg tctttagggt g 141 <210> 83 <211> 138 <212> DNA <213> HPV59 <400> 83 cgtaccagta ttttctacca cgcaggcagt tccagacttc ttacagttgg acatccatat 60 tttaaagtac ctaaaggtgg taatggtaga caggatgttc ctaaggtgtc tgcatatcaa 120 tacagagtat ttagggtt 138 <210> 84 <211> 144 <212> DNA <213> HPV61 <400> 84 cgcaccaact tattttatta tggtggcagt tcccgtctgc ttactgtagg acatccctat 60 tgtagtttgc agcttgatgg gctgcagggc aagaaaaaca ctatccccaa ggtgtctggc 120 tatcaatata gggtgtttag ggta 144 <210> 85 <211> 138 <212> DNA <213> HPV62 <400> 85 cgcaccaacc ttttttatta tgggggcagc tcccgccttc ttactgtggg acatccatat 60 tgtactttac aggttggcca gggtaaacgg gccaccattc ctaaggtgtc tgggtatcag 120 Page 17 WO 2007/057669 PCT/GB2006/004266 P38434WO Genoid„ST25 tacagggtgt ttcgtgtg 138 <210> 86 <211> 135 <212> DNA <213> HPV66 <400> 86 cgtaccagta tattttatca tgcaggtagc tctaggttgc ttgctgttgg ccatccttat 60 tactctgttt ccaaatctgg taccaaaaca aacatcccta aagttagtgc atatcagtat 120 agagtgttta gggta 135 <210> 87 <211> 141 <212> DNA <213> HPV67 <400> 87 cgcacaagca tttactatta cgctggtagc tccagacttt tagctgtagg ccatccttac 60 ttttccattc ctaatccctc caacactaaa aaggtgttag tgcccaaggt gtcaggtttg 120 cagtataggg tatttagggt t 141 <210> 88 <211> 138 <212> DNA <213> HPV68 <400> 88 cgcactggca tgtattacta tgctggtaca tctaggttat taactgtagg ccatccatat 60 tttaaggttc ctatgtctgg gggccgcaag cagggcattc ctaaggtgtc tgcatatcaa 120 tacagagtgt ttagggtt 138 <210> 89 <211> 134 <212> DNA <213> HPV69 <400> 89 cgcaccggat atattactat gcaggcagct ctcgattatt aactttgggt catccctatt 60 ttccaattcc taaatctggt tcaacagcag aaattcctaa agtgtctgct taccaatata 120 gggtttttcg tgtt 134 <210> 90 <211> 138 <212> DNA <213> HPV70 <400> 90 cgtacaggca tatattatta tgctggaagc tctcgcttat taacagtagg gcatccttat 60 Page 18 WO 2007/057669 PCT/GB2006/004266 P38434WO Genoid.ST25 tttaaggtac ctgtaaatgg tggccgcaag caggaaatac ctaaggtgtc tgcatatcag 120 tatagggtat ttagggta 138 <210> 91 <211> 141 <212> DNA <213> HPV72 <400> 91 cgcaccaacc tctattatta tggtggcagt tctcgtctac taactgtagg acatccttac 60 tgtgccatac ctctcaacgg acagggcaaa aaaaacacca ttcctaaggt ttcggggtat 120 caatacaggg tgtttagagt a 141 <210> 92 <211> 138 <212> DNA <213> HPV73 <400> 92 agaacaaata tatattatta tgcaggtagc acacgtttgt tggctgtggg acacccatat 60 tttcctatca aggattctca aaaacgtaaa accatagttc ctaaagtttc aggtttgcaa 120 tacagggtgt ttaggctt 138 <210> 93 <211> 132 <212> DNA <213> HPV74 <400> 93 cgcaccaaca tcttttatca tgctagcagt tctagactac ttgctgtagg aaatccctat 60 ttccctataa aacaggttaa caaaacagtt gttcctaaag tgtctggata tcaatttagg 120 gtgtttaagg tg 132 <210> 94 <211> 141 <212> DNA <213> HPV81 <400> 94 cgcaccaacc ttttttatta tgggggcagt tcccgccttc ttactgtagg gcatccatat 60 tgtacattaa ctattggtac ccaaggaaag cgttccacta ttcccaaggt gtctgggtat 120 cagtaccggg tgtttcgtgt g 141 <210> 95 <211> 135 <212> DNA <213> HPV82 <400> 95 Page 19 WO 2007/057669 PCT/GB2006/004266 P38434WO Genoid.ST25 cgcaccggca tatattatta tgcaggcagt tccagactta ttaccttagg acatccatat 60 ttttcaatac ccaaaaccaa tacacgtgct gaaataccta aggtatctgc ctttcagtat 120 agggtgttta gggta 135 <210> 96 <211> 141 <212> DNA <213> HPV83 <400> 96 cgcaccaacc tcttttatta cggtggcagc tccagacttc ttaccgtagg acatccatat 60 tatcctgtac aggttaatgg tcaaggaaaa aaagccacta tccccaaggt ttctggctac 120 caatataggg tgtttcgcat t 141 <210> 97 <211> 150 <212> DNA <213> HPV84 <400> 97 cgcaccaact tattttatta tggtggtagt tctcgcctgc ttactgtggg acatccatat 60 tattctgttc ctgtgtctac ccctgggcaa aacaacaaaa aggccactat ccccaaggtt 120 tctgggtatc aatacagggt gtttagggtc 150 <210> 98 <211> 138 <212> DNA <213> HPV85 <400> 98 cgtaccagta cattttatca tgctggcagc tctaggcttc taaccgttgg acatccatac 60 tataaagtta cctcaaatgg aggccgcaag caagacattc ctaaagtgtc tgcctatcag 120 tatcgagtgt ttcgggtt 138 <210> 99 <211> 153 <212> DNA <213> HPV86 <400> 99 cgtaccaacc tattttatta tggtggtagt tcccgcttgc ttactgtggg ccatccatat 60 tatcctgtta ctgtttcctc cagccctgga caaaacaaca aaaaggccaa tattcccaag 120 gtttcggggt atcaatacag ggtttttagg gtg 153 <210> 100 <211> 147 <212> DNA <213> HPV87 Page 20 WO 2007/057669 PCT/GB2006/004266 P38434WO Genoid.ST25 <400> 100 cgcaccaact tattttatta tggtggcagt tctcgcctgc ttactgtggg tcacccttac 60 tatccagtta ctgttaccac ccctggtcag aacaagaaat ccaatattcc aaaggtgtct 120 ggctatcagt acagggtgtt tcgggtg 147 <210> 101 <211> 141 <212> DNA <213> HPV89 <400> 101 cgtaccaacc tgtactatta tggaggcagc tcccgcctta ttacagttgg ccacccttat 60 tatactgtac aggtcaatgg tgctaacaaa aaggccaaca tacctaaggt atcagggtat 120 caatacaggg tatttagggt a 141 <210> 102 <211> 141 <212> DNA <213> HPV90 <400> 102 agaacaaaca tatattatta tgcaggcagt tcccgactgt taactgttgg ccatccttat 60 tttgctatca aaaagcaatc aggaaaaaac cctatagtgg ttcccaaggt gtctggatat 120 caatataggg tgtttagggt a 141 <210> 103 <211> 135 <212> DNA <213> HPV91 <400> 103 cgcaccaact tattttacca tgctggcagt tcccgtttac tggctgtggg ccaccctttt 60 tttcctataa aaaataattc tggtaaagta attgttccta aagtttcagg tcaccaatat 120 agggtgttta gagtt 135 <210> 104 <211> 140 <212> DNA <213> HPV-IC <400> 104 cggacgaatg tttattacca gatagataga gatagatacc catatacaga taatgacata 60 gatccccata gacagtttat acagatcagt agcagttttt atatatgaga tgatgatagc 120 aatacagagt atttagggta 140 <210> 105 <211> 25 Page 21 WO 2007/057669 PCT/GB2006/004266 P38434WO Genoid.ST25 <212> DNA <213> Artificial <220> <223> Probe <400> 105 aaaacagttg taccaaaggt gtctg 25 <210> 106 <211> 20 <212> DNA <213> Artificial <220> <223> Probe <400> 106 caaaaaggcc aaataagaca 20 <210> 107 <211> 19 <212> DNA <213> Artificial <220> <223> Probe <400> 107 cccccttaaa aattcctct 19 <210> 108 <211> 20 <212> DNA <213> Arti fi ci al <220> <223> Probe <400> 108 atacgaccag caaacaagac 20 <210> 109 <211> 19 <212> DNA <213> Artificial <220> <223> Probe <400> 109 tatgaatggt ggtcgcaag 19 <210> 110 <211> 21 <212> DNA <213> Artificial Page 22 WO 2007/057669 PCT/GB2006/004266 P38434WO Genoid.ST25 <220> <223> Probe <400> 110 aaaacaccag tagtgctaat g 21 <210> 111 <211> 19 <212> DNA <213> Arti fi ci al <220> <223> Probe <400> 111 ccaaaacaaa cattcccaa 19 <210> 112 <211> 24 <212> DNA <213> Artificial <220> <223> Probe <400> 112 atccatattt taaagtacct aaag 24 <210> 113 <211> 21 <212> DNA <213> Artificial <220> <223> Probe <400> 113 caaatctggt accaaaacaa a 21 <210> 114 <211> 24 <212> DNA <213> Arti fi ci al <220> <223> Probe <400> 114 cccatagaca gtttatacag atca 24 <210> 115 <211> 19 <212> DNA <213> Artificial <220> <223> Probe Page 23 WO 2007/057669 PCT/GB2006/004266 P38434WO Genoid.ST25 <400> 115 ataaaacggg ctaacaaaa 19 <210> 116 <211> 20 <212> DNA <213> Artificial <220> <223> Probe <400> 116 tacctaaaac tggccaaaag 20 <210> 117 <211> 26 <212> DNA <213> Artificial <220> <223> Probe <400> 117 attctaataa aatagcagta cccaag 26 Page 24 </div>